WO2013128755A1 - 吸収性物品 - Google Patents

吸収性物品 Download PDF

Info

Publication number
WO2013128755A1
WO2013128755A1 PCT/JP2012/082087 JP2012082087W WO2013128755A1 WO 2013128755 A1 WO2013128755 A1 WO 2013128755A1 JP 2012082087 W JP2012082087 W JP 2012082087W WO 2013128755 A1 WO2013128755 A1 WO 2013128755A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
chain hydrocarbon
absorber
absorbent article
hydrocarbon moiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2012/082087
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
竜也 田村
野田　祐樹
貴志 野本
卓 小野塚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Unicharm Corp
Original Assignee
Unicharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unicharm Corp filed Critical Unicharm Corp
Priority to CN201280072752.8A priority Critical patent/CN104271090B/zh
Priority to US14/381,928 priority patent/US9375365B2/en
Priority to EP12869942.8A priority patent/EP2821038A4/en
Publication of WO2013128755A1 publication Critical patent/WO2013128755A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/51—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the outer layers of the pads
    • A61F13/511—Topsheet, i.e. the permeable cover or layer facing the skin
    • A61F13/51104—Topsheet, i.e. the permeable cover or layer facing the skin the top sheet having a three-dimensional cross-section, e.g. corrugations, embossments, recesses or projections
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/45—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the shape
    • A61F13/47—Sanitary towels, incontinence pads or napkins
    • A61F13/475—Sanitary towels, incontinence pads or napkins characterised by edge leakage prevention means
    • A61F13/4751—Sanitary towels, incontinence pads or napkins characterised by edge leakage prevention means the means preventing fluid flow in a transversal direction
    • A61F13/4756—Sanitary towels, incontinence pads or napkins characterised by edge leakage prevention means the means preventing fluid flow in a transversal direction the means consisting of grooves, e.g. channels, depressions or embossments, resulting in a heterogeneous surface level
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/51—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the outer layers of the pads
    • A61F13/511—Topsheet, i.e. the permeable cover or layer facing the skin
    • A61F13/513—Topsheet, i.e. the permeable cover or layer facing the skin characterised by its function or properties, e.g. stretchability, breathability, rewet, visual effect; having areas of different permeability
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/20—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing organic materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/26—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/51—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the outer layers of the pads
    • A61F13/511—Topsheet, i.e. the permeable cover or layer facing the skin
    • A61F2013/51186—Topsheet, i.e. the permeable cover or layer facing the skin specially shaped topsheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/51—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the outer layers of the pads
    • A61F13/511—Topsheet, i.e. the permeable cover or layer facing the skin
    • A61F13/513—Topsheet, i.e. the permeable cover or layer facing the skin characterised by its function or properties, e.g. stretchability, breathability, rewet, visual effect; having areas of different permeability
    • A61F2013/51355—Topsheet, i.e. the permeable cover or layer facing the skin characterised by its function or properties, e.g. stretchability, breathability, rewet, visual effect; having areas of different permeability for improving fluid flow

Definitions

  • the present invention relates to absorbent articles such as sanitary napkins, panty liners, incontinence pads, incontinence liners and the like.
  • a sanitary napkin in which the side panel is composed of a liquid-permeable perforated polymer film and a backing sheet is known in the prior art (for example, Patent Document 1). Further, the central absorbent body is provided with a central absorbent body comprising a top sheet, a back sheet and an absorbent body, and a pair of flaps comprising a top sheet and a back sheet extending outward from the center of both sides of the central absorbent body.
  • a sanitary napkin in which the topsheet is in contact with the backsheet at the boundary between the and the flap is known in the prior art (e.g., U.S. Pat. No. 5,958,015).
  • the body fluid absorbed by the absorbent body may temporarily exude from the widthwise edge of the absorbent body.
  • the body fluid exuded from the absorbent penetrates between the liquid-permeable perforated polymer film and the backing sheet in the side panel. And may leak from the width direction of the absorbent article.
  • the conventional absorbent article as described in Patent Document 2 since the top sheet is joined to the back sheet at the boundary between the central absorbent body and the flap, the body fluid exuded from the absorbent body However, there is no penetration between the topsheet and the backsheet at the flaps. However, the body fluid exuding from the absorbent at the widthwise edge of the absorber temporarily loses place between the top sheet and the backsheet, so the topsheet at the widthwise edge of the absorber May leak out from the width direction of the absorbent article.
  • An object of this invention is to provide the absorbent article which can suppress that the bodily fluid which exudeed from the absorber by pressure being applied to an absorbent article may leak from the width direction of an absorbent article.
  • the present invention adopts the following configuration in order to solve the above-mentioned problems. That is, according to the present invention, the liquid-permeable top sheet provided on the skin side having the longitudinal direction and the width direction, the liquid-impermeable back sheet provided on the clothing side, and the longitudinal direction in the width direction An absorbent article comprising an extending edge and a liquid-retaining absorber provided between a top sheet and a back sheet, wherein the absorbent article exudes from the absorber at least outside of both widthwise edges of the absorber. And a plurality of second flow paths, and the plurality of first flow paths extend in the longitudinal direction and are arranged in the width direction, and the plurality of second flow paths are provided. The flow paths connect adjacent first flow paths.
  • FIG. 1 is a plan view of an embodiment of the absorbent article of the present invention.
  • FIG. 2 is a schematic cross-sectional view showing a cross section taken along line AA of FIG.
  • FIG. 3 is a first ridge formed on the top sheet of the wing part and the region outside the widthwise edges of the absorbent body of the main body part in the top sheet of the absorbent article according to an embodiment of the present invention, It is a figure for demonstrating a 2nd protrusion and a bottom part.
  • Drawing 4 is a figure for explaining the 1st projected rim, the 2nd projected rim, and the bottom formed in the field provided with the absorber in the top sheet of the absorptive article of one embodiment of the present invention. It is.
  • FIG. 1 is a plan view of an embodiment of the absorbent article of the present invention.
  • FIG. 2 is a schematic cross-sectional view showing a cross section taken along line AA of FIG.
  • FIG. 3 is a first ridge formed on the top sheet of the
  • FIG. 5 is a figure for demonstrating the flow path comprised from the projection part of a top sheet, and a back sheet.
  • FIG. 6 is a figure for demonstrating the bodily fluid of the wearer who leaked out from the absorber and flowed into the flow path.
  • FIG. 7 is a figure for demonstrating the manufacturing method of the absorbent article of one Embodiment of this invention.
  • FIG. 8 is a view for explaining a recess-forming roll used for producing the absorbent article of one embodiment of the present invention.
  • FIG. 9 is a view for explaining a region where a recess is formed by the recess forming roll in the top sheet.
  • FIG. 10 is a view for explaining an upper stage roll of a drawing gear roll used for manufacturing an absorbent article according to an embodiment of the present invention.
  • FIG. 11 is a view for explaining a lower roll of a drawing gear roll used for manufacturing an absorbent article according to an embodiment of the present invention.
  • FIG. 12 is a view for explaining a top sheet sheet stretched by a stretching gear roll.
  • FIG. 13 is a plan view of a modified example of one embodiment of the absorbent article of the present invention.
  • FIG. 14 is a plan view showing the area outside the widthwise edge of the absorbent body in a modification of the embodiment of the absorbent article of the present invention.
  • FIG. 15 is an electron micrograph of the skin contact surface of the top sheet in the sanitary napkin in which the top sheet contains avian C2L oil fatty acid glyceride.
  • FIG. 16 is a photomicrograph of menstrual blood with or without a blood modifying agent.
  • FIG. 17 is a diagram for explaining a method of measuring surface tension.
  • FIG. 1 is a plan view of an absorbent article according to an embodiment of the present invention
  • FIG. 2 is a schematic cross-sectional view taken along the line AA of FIG.
  • the absorbent article 1 has a liquid-permeable top sheet 2 provided on the skin side (skin contact side), a liquid-impermeable back sheet 3 provided on the clothing side (non-skin contact side), and a top sheet 2 and a back sheet 3, provided on both sides of the main body 10 so as to extend in the width direction from both side edges of the main body 10 including the liquid-retaining absorber 4 provided between the back sheet 3 and And a pair of wing portions 5 provided with the top sheet 2 and the back sheet 3.
  • Reference numeral 51 is a root of the wing 5 (a boundary between the main body 10 and the wing 5).
  • the surface on the opposite side of the surface on the clothing side of the wing portion 5 is constituted by the top sheet 2.
  • An adhesive portion 6 is provided on the surface of the wing portion 5 on the clothes side.
  • the width direction of the absorbent article 1 is the X direction
  • the longitudinal direction is the Y direction
  • the plane direction of the absorbent article 1 is the XY direction.
  • the shape of the main body portion 10 is not particularly limited as long as it is a shape that conforms to the shape of a female body and an underwear, such as a rectangular shape, an oval shape, and an hourglass shape.
  • the longitudinal dimension in the outer shape of the main body 10 is preferably 100 to 500 mm, more preferably 150 to 350 mm. Further, the dimension in the width direction of the outer shape of the main body 10 is preferably 30 to 200 mm, more preferably 40 to 180 mm.
  • the top sheet 2 transfers body fluid such as urine and menstrual blood discharged from the wearer to the absorber 4. At least a portion of the top sheet 2 is liquid permeable and has a number of openings for the passage of body fluids.
  • the top sheet 2 is made of a resin film.
  • the resin film used as the top sheet 2 is made of a copolymer of an olefin and an acrylic ester, another monomer such as vinyl acetate, polyolefin, polyester, polypropylene, polyethylene, polyethylene terephthalate, polyamide, cellulose acetate or the like.
  • the resin film used as the top sheet 2 is particularly preferably a copolymer of an olefin and another monomer, or a polyolefin, from the viewpoint of high flexibility and low irritation to the skin.
  • the basis weight of the top sheet 2 is preferably 1 g / m 2 or more and 40 g / m 2 or less, more preferably 10 g / m 2 or more and 35 g / m 2 or less.
  • the thickness of the resin film which comprises the top sheet 2 becomes like this. Preferably it is 0.01 mm or more and 0.4 mm or less, More preferably, it is 0.1 mm or more and 0.35 mm or less.
  • the thickness of the resin film constituting the top sheet 2 is less than 0.01 mm, the hiding property of the top sheet 2 described below may be too small, and the thickness of the resin film constituting the top sheet 2 is If it exceeds 0.4 mm, the rigidity of the top sheet 2 may be high, and the stimulation of the top sheet 2 given to the wearer's skin may be too strong. Since the top sheet 2 has a ridge portion described later, the apparent thickness of the top sheet 2 is larger than the thickness of the resin film constituting the top sheet 2.
  • the apparent thickness of the top sheet 2 is preferably 0.01 mm or more and 1 mm or less, more preferably 0.1 mm or more and 0.5 mm or less.
  • the top sheet 2 has concealability in order to prevent the body fluid absorbed by the absorber 4 from being seen from the outside.
  • the hiding property of the top sheet 2 is produced by mixing a filler such as titanium oxide into the resin.
  • the filler is titanium oxide
  • the content of titanium oxide is preferably 1% to 50%, more preferably 3% to 15%, based on the weight of the resin film.
  • the content of the titanium oxide is less than 1% with respect to the weight of the resin film, the effect of hiding the body fluid absorbed by the absorber 4 in the top sheet 2 may be too small.
  • sheet forming of the resin containing titanium oxide may be difficult.
  • the top sheet 2 extends in the longitudinal direction, and includes a plurality of first protrusions 21 aligned in the width direction, and a plurality of second protrusions 22 connecting the adjacent first protrusions 21; It has a first projection 21 and a bottom 23 of the base of the second projection 22.
  • FIG. 3 shows the first ridges formed on the region 14 outside the both edges 41 of the absorbent body 4 in the width direction of the top sheet 2 of the main body 10 and the top sheet 2 of the wing 5 (see FIG. 1) It is a figure for demonstrating a 2nd protrusion part and a bottom part.
  • FIG. 4 is for demonstrating the 1st protrusion, the 2nd protrusion, and the bottom part which were formed in the area
  • region 12 in which the absorber 4 in the top sheet 2 of the main-body part 10 is provided (refer FIG. 1).
  • the first ridge, the second ridge, and the bottom formed in the region 12 in the top sheet 2 of the main body 10 in which the absorber 4 is provided are slightly different as described later.
  • the top sheet 2 extends in the longitudinal direction (Y direction) in the regions 14 and the wings 5 outside the both edges 41 in the width direction of the absorber 4, and the width direction (X direction) And a plurality of first protrusions 21 aligned with each other.
  • the shape of the cross section of the first protrusion 21 is, for example, a shape in which a substantially U-shape is turned upside down (hereinafter, referred to as a substantially reverse U-shape).
  • the U-shape can be inverted upside-down when it is deformed, such as rounding corners or changing a straight line into a curve, in the substantially inverted U-shape. included.
  • the substantially inverted U-shape also includes an inverted V-shape, an M-shape, and a trapezoid.
  • the adjacent first protrusions 21 are connected via the plurality of second protrusions 22. It is preferable that the second ridges 22 extend in a direction oblique to the first ridges 21 extending in the longitudinal direction (Y direction). For example, it is preferable that an angle between the first protrusion 21 and the second protrusion 22 be 10 degrees or more and 170 degrees or less.
  • the shape of the cross section of the second protrusion 22 when the second protrusion 22 is cut in a direction orthogonal to the direction in which the second protrusion 22 extends is, for example, a substantially reverse V-shape. .
  • FIG. 5 is a view for explaining a flow path formed of the ridges 21 and 22 of the top sheet 2 and the back sheet 3.
  • a hollow structure is formed.
  • the body fluid 31 that has leaked from the absorber 4 flows into the hollow structure. That is, the first protrusion 21 and the second protrusion 22 together with the back sheet 3 described later form a flow path for pouring the body fluid 31 into.
  • the body fluid 31 which has flowed into the flow path constituted by the second ridge 22a and the back sheet 3 is constituted by the first ridge 21a and the back sheet 3.
  • the body fluid that has flowed into the flow path formed of the first ridge 21 a and the back sheet 3 is longitudinally (in the Y direction) in the flow path formed of the first ridge 21 a and the back sheet 3 Flows to After flowing in the longitudinal direction (Y direction), the body fluid 31 passes through the flow path formed of the second ridge 22 b and the back sheet 3 to form the adjacent first ridge 21 b and the back sheet 3.
  • the body fluid that has flowed into the flow path formed of the first ridge 21 b and the back sheet 3 is longitudinally (in the Y direction) in the flow path formed of the first ridge 21 b and the back sheet 3 Flows to After flowing in the longitudinal direction (Y direction), the body fluid 31 is separated from the first ridge 21 c and the back sheet 3 adjacent to each other through the flow path formed of the second ridge 22 c and the back sheet 3. Flow into the flow path composed of In this manner, the body fluid 31 flows in the longitudinal direction (Y direction) in the flow path formed of the first ridge 21 and the back sheet 3, and thereafter, the body fluid 31 forms the second ridge.
  • the emitted body fluid spreads in the width direction (X direction) between the top sheet 2 and the back sheet 3.
  • the bodily fluid 31 which exudes from the absorber 4 spreads in the width direction (X direction), and when the pressure is applied to the absorbent article 1, the bodily fluid 31 which exudes from the absorber 4 is absorbed. Leakage from the width direction of the sex article 1 can be suppressed.
  • the number of first protrusions 21 per cm in the width direction is preferably 3 or more, more preferably 5 or more. If the number of first protrusions 21 per cm in the width direction is 2 or less, the amount of body fluid that can be accumulated in the first protrusions 21 decreases, and the body fluid exuded from the absorber is absorbed It may leak from the width direction of the sex goods.
  • the length in the longitudinal direction (Y direction) of the second ridge portion 22 is preferably 0.3 mm or more and 5 mm or less, and more preferably 0.5 mm or more and 3 mm or less.
  • the length in the longitudinal direction (Y direction) of the second ridge 22 is smaller than 0.3 mm, the body fluid flowing into the first ridge 21 passes through the second ridge 22. It may be difficult to flow into the adjacent first protrusion 21, and there may be a case where the body fluid which has lost its place of spot exudes out of the top sheet 2.
  • the length in the longitudinal direction (Y direction) of the second protrusion 22 is greater than 5 mm, the body fluid flowing into the first protrusion 21 elongates in the first protrusion 21. Before flowing in the direction (Y direction), it may flow into the adjacent first ridge 21 via the second ridge 22 and the body fluid exuded from the absorber is from the width direction of the absorbent article May leak.
  • the first protrusion 21 and the second protrusion 22 will be present.
  • the first protrusion 21 and the second protrusion 22 impart a soft touch to the surface of the absorbent article 1. Therefore, this makes the skin contact of the undergarment of the undergarment when wearing the undergarment with the absorbent article 1 better.
  • the top sheet 2 of the region 12 of the main body 10 in which the absorber 4 is provided is the region 14 and the wing 5 outside the both edges 41 of the main body 10 in the width direction of the absorber 4.
  • the first protrusion 21, the second protrusion 22 and the bottom 23 are included.
  • the first ridge 21, the second ridge 22 and the bottom 23 of the top sheet 2 in the region 12 of the main body 10 in which the absorbent body 4 is provided have a blood-modified surface described later on the skin side surface.
  • the agent layer 24 is further included.
  • the first ridge 21 of the top sheet 2 in the area 12 where the absorber 4 is provided further includes an opening 25 described later.
  • the first protrusion 21 of the top sheet 2 of the region 12 of the main body 10 in which the absorber 4 is provided has a plurality of openings 25 aligned in the longitudinal direction (Y direction) on both side surfaces 26 thereof.
  • the body fluid of the wearer discharged to the top sheet 2 of the area 12 where the absorber 4 of the main body 10 is provided passes through the opening 25 and moves to the absorber 4.
  • the body fluid of the wearer discharged to the top sheet 2 by the substantially U shape in the width direction (X direction) formed by the two adjacent first ridges 21 and the bottom 23 is the bottom 23 Gather quickly towards you.
  • the body fluid flowing toward the bottom 23 passes through the opening 25 provided on the side surface 26 of the first protrusion 21 and reaches the absorber 4 before reaching the bottom 23.
  • the body fluid accumulated in the bottom portion 23 also passes through the opening 25 provided in the side surface 26 of the first protrusion 21 and flows to the absorber 4. Therefore, the body fluid of the wearer is quickly absorbed by the absorbent body 4 by the opening 25 provided on the side surface 26 of the first protrusion 21. In addition, the amount of body fluid remaining in the top sheet 2 can be reduced by the openings 25 provided on the side surface 26 of the first protrusion 21.
  • a blood modifying agent is applied to the skin side surface of the top sheet 2 of the region 12 where the absorber 4 of the main body portion 10 is provided, and a blood modifying layer 24 is formed on the skin contacting side surface of the top sheet 2 May be formed.
  • the blood modifier layer 24 can prevent the body fluid of the wearer, in particular, the highly viscous menstrual blood from remaining on the surface of the top sheet 2.
  • the blood modifying agent layer 24 will be described in detail later.
  • the top The feel of the sheet 2 becomes good.
  • the first ridge portion is less likely to be crushed, so the first ridge is formed on the top sheet 2 of the region 12 of the main body portion 10 where the absorber 4 is provided. It is preferable to provide both the part and the second protrusion.
  • the back sheet 3 shown in FIGS. 1 and 2 prevents the body fluid absorbed by the absorber 4 from leaking out.
  • the back sheet 3 is made of a material that is impermeable to body fluid.
  • a hydrophobic non-woven fabric an impermeable plastic film such as polyethylene and polypropylene or a laminate sheet of non-woven fabric and an impermeable plastic film, or the like is used.
  • an SMS non-woven fabric in which a highly water-resistant melt-blown non-woven fabric is sandwiched by strong spunbond non-woven fabrics may be used as the back sheet 3.
  • the back sheet 3 overlaps with the top sheet 2
  • the back sheet 3 is a body fluid 31 together with the first ridge 21 and the second ridge 22 formed on the top sheet 2 described above.
  • Form a flow path for pouring The back sheet 3 is joined to the bottom 23 of the top sheet 2 using an adhesive such as a hot melt adhesive.
  • the absorber 4 absorbs and holds the body fluid. It is preferable that the absorber 4 is bulky, hard to lose its shape, and less in chemical stimulation.
  • a composite absorbent made of fluff pulp or air-laid non-woven fabric and super absorbent polymer (SAP) is used as the absorbent 4.
  • SAP super absorbent polymer
  • the composite absorber may be covered with a liquid permeable material such as a tissue.
  • artificial cellulose fibers such as chemical pulp, cellulose fibers, rayon and acetate may be used.
  • the basis weight of the absorbent fiber such as pulp in the composite absorbent is preferably 100 g / m 2 or more and 800 g / m 2 or less, and the mass ratio of the superabsorbent polymer in the composite absorbent is the absorbency
  • the fiber content is preferably 100% to 10% to 65%.
  • the basis weight of a liquid-permeable material such as a tissue covering the composite mixture is preferably 12 g / m 2 or more and 30 g / m 2 or less.
  • the air-laid non-woven fabric of the composite mixture for example, a non-woven fabric in which pulp and synthetic fibers are heat-sealed or a non-woven fabric in which pulp and synthetic fibers are fixed with a binder can be used.
  • the superabsorbent polymer of the composite absorbent has a three-dimensional network structure in which a water-soluble polymer is appropriately crosslinked.
  • the absorbent polymer absorbs 30 to 60 times as much water as the volume of absorbent polymer before absorbing water.
  • this absorbable polymer is essentially water insoluble.
  • the absorbent polymer does not release the water once absorbed, even if some pressure is applied.
  • this absorbent polymer for example, starch-based, acrylic acid-based or amino acid-based particulate or fibrous polymers are used.
  • the shape and structure of the absorber 4 can be changed as needed, but the total amount of absorption of the absorber 4 needs to correspond to the designed insertion amount as the absorbent article 1 and the desired application.
  • the size, absorption capacity and the like of the absorber 4 change depending on the application.
  • the edge 41 in the width direction of the absorber 4 is curved so as to protrude in the width direction (X direction).
  • the first protrusion 21 provided on the top sheet 2 in the area 14 outside the both edges 41 in the width direction of the absorber 4 proceeds in the longitudinal direction (Y direction) And the widthwise edge 41 of the absorber 4. Therefore, the body fluid 31 which has flowed in the longitudinal direction (Y direction) in the flow path constituted by the first ridge 21 and the back sheet, and which is exuded from the absorber 4 is absorbed by the absorber 4 again. .
  • Absorber 4 is bonded to back sheet 3 using a hot melt adhesive. Thereby, peeling of the absorber 4 from the back sheet 3 can be suppressed.
  • the wing portion 5 is provided on the absorbent article 1 in order to stably fix the absorbent article 1 to the undergarment.
  • the absorbent article 1 can be stably fixed to the undergarment by bending the wing portion 5 to the outer surface side of the undergarment and then sticking it to the crotch portion of the undergarment through the adhesive portion 6.
  • the adhesive portion 6 fixes the absorbent article 1 to the crotch portion of the undergarment.
  • an adhesive which forms the adhesion part 6 what is a styrene-type polymer, a tackifier, and a plasticizer as a main component, for example is used suitably.
  • the styrene-based polymer include styrene-ethylene-butylene-styrene block copolymer, styrene-butylene polymer, styrene-butylene-styrene block copolymer, and styrene-isobutylene-styrene copolymer. Or a blend of two or more polymers.
  • styrene-ethylene-butylene-styrene block copolymer is preferable in that the thermal stability is good.
  • tackifier and the plasticizer those which are solid at normal temperature can be preferably used, and as the tackifier, for example, C5 petroleum resin, C9 petroleum resin, dicyclopentadiene petroleum resin, rosin petroleum resin And polyterpene resins, terpene phenol resins, etc.
  • the plasticizer include, in addition to monomer plasticizers such as triflecil phosphate, dibutyl phthalate and dioctyl phthalate, polymer plasticizers such as vinyl polymers and polyesters.
  • the top sheet 2 and the absorbent body 4 have compressed grooves 7 extending from the top sheet 2 to the inside of the absorbent body 4 which are compressed in the thickness direction by embossing.
  • the squeeze groove 7 suppresses the diffusion of the body fluid discharged to the central portion of the absorbent article 1 (the portion facing the outlet of the body fluid of the wearer) in the width direction (X direction). Moreover, it can suppress that the top sheet 2 peels from the absorber 4 by this.
  • the pressing groove 7 surrounds the central portion of the absorbent article 1 and has a continuous and substantially annular shape.
  • the pressing groove 7 surrounding the center part of the absorbent article 1 may be partially interrupted. That is, the pressing groove 7 may have a discontinuous and substantially annular shape.
  • the compression bonding of the top sheet 2 to the back sheet 3 by heat embossing forms the seal portions 8 on both sides in the longitudinal direction and both sides in the width direction of the absorbent article 1.
  • the top sheet 2 can be prevented from peeling off from the back sheet 3.
  • both ends of the flow path constituted by the first ridge 21 and the back sheet 3 are compressed and sealed by the sealing portions 8 on both sides in the longitudinal direction.
  • both ends of the flow path formed of the first ridge 21 and the back sheet 3 are closed, the first ridge 21 and the back sheet 3 are formed.
  • the body fluid of the wearer that has flowed in a large amount through the flow path can be prevented from leaking from both ends in the longitudinal direction of the absorbent article 1.
  • the blood modifying agent of the blood modifying agent layer 24 is a blood modifying agent having an IOB of about 0.00 to about 0.60, a melting point of about 45.degree. C. or less, 100 g of water at 25.degree. It has a water solubility of 00 to about 0.00 to about 0.05 g.
  • IOB Inorganic Organic Balance
  • IOB value calculated by inorganic value / organic value.
  • the IOB is about 0.00 to about 0.60, preferably about 0.00 to about 0.50, and about 0.00 to about 0.40. More preferred is about 0 to about 0.30. This is because the lower the IOB, the higher the organicity and the higher the affinity to blood cells.
  • the "melting point” means the peak top temperature of an endothermic peak when changing from solid state to liquid state when measured at a temperature rising rate of 10 ° C./min in a differential scanning calorimeter.
  • the melting point can be measured, for example, using a DSC-60 type DSC measurement apparatus manufactured by Shimadzu Corporation.
  • the blood modifying agent may be liquid or solid at room temperature as long as it has a melting point of about 45 ° C. or less, ie, even if the melting point is about 25 ° C. or more, or less than about 25 ° C. It may well have a melting point such as, for example, about -5.degree. C., about -20.degree. The reason why the melting point of the blood modifying agent is about 45 ° C. or less will be described later.
  • the vapor pressure of the blood modifying agent is preferably about 0 to about 200 Pa at 25 ° C. (1 atm), more preferably about 0 to about 100 Pa, and further preferably about 0 to about 10 Pa. Preferably, about 0 to about 1 Pa is even more preferred, and about 0.0 to about 0.1 Pa is even more preferred.
  • the vapor pressure is preferably about 0 to about 700 Pa and about 0 to about 100 Pa at 40 ° C. (1 atm).
  • the melting point of the blood modifying agent can be properly used depending on the weather, the length of wearing time, and the like. For example, in areas where the average temperature is less than about 10 ° C, menstrual blood may be excreted and then cooled by the ambient temperature by employing a blood modifying agent having a melting point of less than about 10 ° C. It is believed that blood modifying agents can stably modify blood.
  • the melting point of the blood modifying agent is preferably higher in the range of 45 ° C. or less. It is because it is hard to be affected by sweat, friction at the time of wearing, etc., and it is difficult for the blood modifying agent to move even when worn for a long time.
  • a water solubility of 0.00 to 0.05 g For a water solubility of 0.00 to 0.05 g, add a 0.05 g sample to 100 g deionized water at 25 ° C., allow to stand for 24 hours, and after 24 hours, lightly stir as needed, Then, it can be measured by visually evaluating whether the sample has dissolved.
  • dissolving includes cases where the sample is completely dissolved in deionized water to form a homogeneous mixture and cases where the sample is completely emulsified. "Complete” means that there is no clump of sample in deionized water.
  • the surface of the top sheet is coated with a surfactant for the purpose of changing blood surface tension and the like to rapidly absorb the blood.
  • the surfactant generally has high water solubility
  • the surfactant-coated top sheet is compatible with hydrophilic components (such as plasma) in the blood, rather the blood remains on the top sheet.
  • hydrophilic components such as plasma
  • solubility in 100 g of water at 25 ° C. may be simply referred to as “water solubility”.
  • the weight average molecular weight means a value in terms of polystyrene, which is determined by gel permeation chromatography (GPC).
  • GPC measurement conditions include the following. Model: High-performance liquid chromatogram Lachrom Elite manufactured by Hitachi High-Technologies Corporation Column: Showa Denko KK SHODEX KF-801, KF-803 and KF-804 Eluent: THF Flow rate: 1.0 mL / min Implanted volume: 100 ⁇ L Detection: RI (differential refractometer)
  • the weight average molecular weight described in the Example of this specification is measured based on the said conditions.
  • the above blood modifying agent is preferably selected from the following (i) to (iii), (I) Hydrocarbons, (Ii) from a carbonyl group (-CO-) and an oxy group (-O-) inserted between (ii-1) a hydrocarbon moiety and (ii-2) a C-C single bond of the above-mentioned hydrocarbon moiety
  • hydrocarbon means a compound consisting of carbon and hydrogen, and is a chain hydrocarbon, for example, paraffinic hydrocarbon (also referred to as alkane not containing double bond and triple bond) Olefinic hydrocarbons (containing one double bond, also called alkenes), acetylenic hydrocarbons (containing one triple bond, also called alkynes), and a group consisting of double bonds and triple bonds And hydrocarbons containing two or more bonds selected from, as well as cyclic hydrocarbons such as aromatic hydrocarbons and alicyclic hydrocarbons.
  • paraffinic hydrocarbon also referred to as alkane not containing double bond and triple bond
  • Olefinic hydrocarbons containing one double bond, also called alkenes
  • acetylenic hydrocarbons containing one triple bond, also called alkynes
  • hydrocarbons containing two or more bonds selected from, as well as cyclic hydrocarbons such as aromatic hydrocarbons and alicyclic hydrocarbons.
  • the hydrocarbon is preferably a chain hydrocarbon and an alicyclic hydrocarbon, more preferably a chain hydrocarbon, a paraffin hydrocarbon, an olefin hydrocarbon and two double bonds. It is more preferable that it is the hydrocarbon (it does not contain a triple bond) which contains above, and it is still more preferable that it is a paraffinic hydrocarbon.
  • the chained hydrocarbons include straight chained hydrocarbons and branched chained hydrocarbons.
  • each oxy group (—O—) is not adjacent. Accordingly, the compounds (ii) and (iii) do not include compounds in which the oxy group is continuous (so-called peroxides).
  • At least one hydrogen atom of the hydrocarbon moiety is a hydroxyl group (-) rather than a compound in which at least one hydrogen atom of the hydrocarbon moiety is substituted with a carboxyl group (-COOH).
  • Compounds substituted with OH) are preferred.
  • Table 1 since the carboxyl group binds to metals and the like in blood, and the inorganic value greatly increases from 150 to 400 or more, the blood modifying agent having a carboxyl group is used at the time of use This is because the IOB value may exceed about 0.60 and the affinity to blood cells may be reduced.
  • the above blood modifying agent comprises the following (i ') to (iii'), (I ') hydrocarbons, (Ii ') (ii'-1) a hydrocarbon moiety, and (ii'-2) a carbonyl bond (-CO-), an ester bond (-COO) inserted between a C-C single bond of the above-mentioned hydrocarbon moiety -), A compound having one or more same or different bonds selected from the group consisting of carbonate bond (-OCOO-), and ether bond (-O-), and (iii ') (iii'-) 1) Carbonyl bond (-CO-), ester bond (-COO-), carbonate bond (-OCOO) inserted between the hydrocarbon moiety and the C-C single bond of the above-mentioned hydrocarbon moiety (iii'-2) A carboxyl group (-), and one or more, same or different bond selected from the group consisting of an ether bond (-O-) and (iii'
  • the blood modifying agent has about 1.8 or less carbonyl bonds (-CO-) and 2 or less ester bonds (-COO-) per 10 carbon atoms in the hydrocarbon moiety. About 1.5 or less carbonate bond (-OCOO-), about 6 or less ether bond (-O-), about 0.8 or less carboxyl group (-COOH), and / or hydroxyl group (-OH) Or a compound having about 1.2 or less).
  • the above blood modifying agent is any of the following (A) to (F), (A) A compound having (A1) a chain hydrocarbon moiety and 2 to 4 hydroxyl groups replacing the hydrogen atom of the chain hydrocarbon moiety, (A2) a chain hydrocarbon moiety, and the above chain Ester with a compound having one carboxyl group replacing the hydrogen atom of the cyclic hydrocarbon moiety, (B) A compound having (B1) a chain hydrocarbon moiety and 2 to 4 hydroxyl groups replacing the hydrogen atom of the chain hydrocarbon moiety, (B2) a chain hydrocarbon moiety, and the above chain Ether with a compound having one hydroxyl group replacing the hydrogen atom of the cyclic hydrocarbon moiety, (C) a carboxylic acid, a hydroxy acid, an alkoxy acid or an oxo acid containing a (C1) linear hydrocarbon moiety and 2 to 4 carboxyl groups replacing the hydrogen atom of the linear hydrocarbon moiety; C2) an ester of a compound having a chain hydrocarbon moiety
  • a compound having (A1) a chain hydrocarbon moiety and 2 to 4 hydroxyl groups replacing the hydrogen atom of the chain hydrocarbon moiety, (A2) a chain hydrocarbon moiety, and the above chain Ester with a compound having one carboxyl group replacing hydrogen atoms in the cyclic hydrocarbon moiety (hereinafter sometimes referred to as “compound (A)”) has the above-mentioned IOB, melting point and water solubility And all hydroxyl groups may not be esterified.
  • (A1) a compound having a chain hydrocarbon portion and 2 to 4 hydroxyl groups replacing the hydrogen atom of the above chain hydrocarbon portion (hereinafter sometimes referred to as “compound (A1)”)
  • chain hydrocarbon tetraols such as alkanetetraols such as pentaerythritol
  • chain hydrocarbon triols such as alkanetriols such as glycerin
  • chain hydrocarbon diols such as alkane diols such as Glycol is mentioned.
  • Examples of (A2) a compound having a chain hydrocarbon portion and one carboxyl group replacing the hydrogen atom of the chain hydrocarbon portion include, for example, And compounds in which one hydrogen atom on a hydrocarbon is substituted with one carboxyl group (—COOH), such as fatty acid.
  • Examples of the compound (A) include an ester of (a 1 ) chain hydrocarbon tetraol and at least one fatty acid, an ester of (a 2 ) chain hydrocarbon triol and at least one fatty acid, and (a 3 And esters of linear hydrocarbon diols and at least one fatty acid.
  • the ester of the above linear hydrocarbon tetraol and at least one fatty acid may be, for example, the following formula (1): Tetraester of pentaerythritol with fatty acid, the following formula (2): Triester of pentaerythritol with fatty acid, the following formula (3): A diester of pentaerythritol with fatty acid, the following formula (4): And monoesters of fatty acid with pentaerythritol. (Wherein, R 1 to R 4 are each a chain hydrocarbon)
  • esters of pentaerythritol and fatty acids have the above IOB, melting point and water solubility
  • saturated fatty acids such as C 2 to C 30 saturated fatty acids, for example, acetic acid (C 2 ) (C 2 represents a carbon number, R 1 C, R 2 C, R 3 C or R 4 C, which corresponds to the carbon number of R 2 C, hereinafter the same), propanoic acid (C 3 ), butanoic acid (C 4 ) and isomers thereof, for example, 2-methylpropanoic acid (C 4) ), pentanoic acid (C 5) and isomers thereof such as 2-methylbutanoic acid (C 5), 2,2-dimethyl propanoic acid (C 5), hexanoic acid (C 6), heptanoic acid (C 7) Oct
  • the fatty acids can also be unsaturated fatty acids.
  • unsaturated fatty acids include C 3 -C 20 unsaturated fatty acids such as monounsaturated fatty acids such as crotonic acid (C 4 ), myristoleic acid (C 14 ), palmitoleic acid (C 16 ), Oleic acid (C 18 ), elaidic acid (C 18 ), vacenic acid (C 18 ), gadeuric acid (C 20 ), eicosenic acid (C 20 ), etc., diunsaturated fatty acids such as linoleic acid (C 18 ), Eicosadienoic acid (C 20 ) and the like, triunsaturated fatty acids such as linolenic acid, for example ⁇ -linolenic acid (C 18 ) and ⁇ -linolenic acid (C 18 ), pinolenic acid (C 18 ), eleostearic acid, For example, ⁇ -eleostearic acid (C 18
  • the ester of pentaerythritol and fatty acid is an ester of pentaerythritol and fatty acid derived from saturated fatty acid, that is, an ester of pentaerythritol and saturated fatty acid, in consideration of the possibility of modification by oxidation etc. preferable.
  • the ester of pentaerythritol and a fatty acid in order to make IOB small and make it more hydrophobic, it is preferable to be a diester, a triester or a tetraester, and a triester or a tetraester is more preferable. And tetra-esters are more preferred.
  • the total carbon number of fatty acids constituting the tetraester of pentaerythritol and fatty acid that is, in the above formula (1), R 1 C, R 2 C, R 3 C and When the total number of carbons in the R 4 C portion is 15, the IOB is 0.60. Therefore, in the case of tetraester of pentaerythritol and fatty acid, IOB satisfies the requirement of about 0.00 to about 0.60 when the total number of carbons is about 15 or more.
  • Examples of the tetraester of pentaerythritol and fatty acid include pentaerythritol, hexanoic acid (C 6 ), heptanoic acid (C 7 ), octanoic acid (C 8 ), for example, 2-ethylhexanoic acid (C 8 ), These include tetraesters with nonanoic acid (C 9 ), decanoic acid (C 10 ) and / or dodecanoic acid (C 12 ).
  • the total carbon number of the fatty acid constituting the triester of pentaerythritol and fatty acid that is, the R 1 C, R 2 C and R 3 C moieties in the above formula (2)
  • the IOB is 0.58 when the sum of the carbon numbers of these is 19. Therefore, in the case of the triester of pentaerythritol and fatty acid, IOB satisfies the requirement of about 0.00 to about 0.60 when the total carbon number of fatty acid is about 19 or more.
  • the total carbon number of fatty acids constituting the diester of pentaerythritol and fatty acid that is, the total carbon number of R 1 C and R 2 C in the above formula (3) is In the case of 22, the IOB is 0.59. Accordingly, in the diester of pentaerythritol and fatty acid, IOB satisfies the requirement of about 0.00 to about 0.60 when the total carbon number of fatty acid is about 22 or more.
  • esters of pentaerythritol and fatty acid examples include Unistar H-408 BRS, H-2408 BRS-22 (mixed product), etc. (all manufactured by NOF Corporation).
  • the ester of the above linear hydrocarbon triol and at least one fatty acid may be, for example, the following formula (5): Triester of glycerin and fatty acid, the following formula (6): A diester of glycerin and a fatty acid, and the following formula (7): (Wherein, each of R 5 to R 7 is a chain hydrocarbon) And monoesters of glycerin and fatty acids.
  • fatty acids (R 5 COOH, R 6 COOH and R 7 COOH) constituting the ester of glycerin and fatty acid if the ester of glycerin and fatty acid satisfies the requirements of the above IOB, melting point and water solubility
  • the fatty acids listed in the “ester of (a 1 ) chain hydrocarbon tetraol and at least one fatty acid” are not particularly limited, and examples thereof include saturated fatty acids and unsaturated fatty acids, which are modified by oxidation etc. In consideration of the possibility of doing so, an ester of glycerin and a fatty acid derived from a saturated fatty acid, that is, an ester of glycerin and a saturated fatty acid is preferable.
  • ester of glycerol and a fatty acid in order to make IOB small and to make it more hydrophobic, it is preferable that it is diester or triester, and it is more preferable that it is triester.
  • triester of glycerin and fatty acid is also referred to as triglyceride, for example, triester of glycerin and octanoic acid (C 8 ), triester of glycerin and decanoic acid (C 10 ), glycerin and dodecanoic acid (C 12 And triesters of glycerin with two or three fatty acids, and mixtures thereof.
  • Examples of the triester of the above glycerin and two or more fatty acids include triester of glycerin and octanoic acid (C 8 ) and decanoic acid (C 10 ), glycerin, octanoic acid (C 8 ), decane Acid (C 10 ) and triester with dodecanoic acid (C 12 ), glycerin and octanoic acid (C 8 ), decanoic acid (C 10 ), dodecanoic acid (C 12 ), tetradecanoic acid (C 14 ), hexadecanoic acid Examples thereof include triesters with (C 16 ) and octadecanoic acid (C 18 ).
  • the total carbon number of fatty acids constituting the triester of glycerin and fatty acid ie, R 5 C in the formula (5)
  • the sum of the carbon numbers of the R 6 C and R 7 C moieties is about 40 or less.
  • the total carbon number of fatty acids constituting the triester of glycerin and fatty acid that is, in the formula (5), the R 5 C, R 6 C and R 7 C moieties
  • the IOB is 0.60. Therefore, in the above-mentioned triesters of glycerin and fatty acid, the IOB satisfies the requirement of about 0.00 to about 0.60 when the total carbon number of fatty acid is about 12 or more.
  • the above-mentioned triester of glycerin and a fatty acid is a so-called fat and is a component that can constitute the human body, and thus is preferable from the viewpoint of safety.
  • tricotic oil fatty acid glyceride NA36
  • PANACET 800 PANACET 800B
  • PANACET 810S avian C2L oil fatty acid glyceride and triCL oil fatty acid glyceride (manufactured by NOF CORPORATION) Etc.).
  • the above-mentioned diester of glycerin and fatty acid is also referred to as diglyceride, for example, a diester of glycerin and decanoic acid (C 10 ), a diester of glycerin and dodecanoic acid (C 12 ), and glycerin and hexadecanoic acid (C 16 ) Included are diesters and diesters of glycerin with two fatty acids, and mixtures thereof.
  • the total carbon number of fatty acids constituting the diester of glycerin and fatty acid ie, the case where the total carbon number of R 5 C and R 6 C moieties in the formula (6) is 16
  • the IOB is 0.58. Therefore, in the case of the diester of glycerin and fatty acid, the IOB satisfies the requirement of about 0.00 to about 0.60 when the total carbon number of fatty acid is about 16 or more.
  • the monoester of glycerin and fatty acid is also referred to as monoglyceride, and examples thereof include icosanoic acid (C 20 ) monoester of glycerin, docosanoic acid (C 22 ) monoester of glycerin and the like.
  • the carbon number of fatty acid constituting the monoester of glycerin and fatty acid that is, in the formula (7), the IOB is 0.59 when the carbon number of the R 5 C portion is 19 It becomes. Therefore, in the monoester of glycerin and fatty acid, the IOB satisfies the requirement of about 0.00 to about 0.60 when the carbon number of the fatty acid is about 19 or more.
  • esters of the above linear hydrocarbon diol and at least one fatty acid include C 2 to C 6 linear hydrocarbon diols, such as C 2 to C 6 glycols, such as ethylene glycol, propylene glycol, butylene And mono- or diesters of glycol, pentylene glycol or hexylene glycol with fatty acids.
  • ester of the above linear hydrocarbon diol and at least one fatty acid for example, the following formula (8): R 8 COOC k H 2k OCOR 9 (8) (Wherein k is an integer of 2 to 6 and R 8 and R 9 are each a chain hydrocarbon) A diester of a C 2 -C 6 glycol with a fatty acid, and the following formula (9): R 8 COOC k H 2k OH (9) (Wherein k is an integer of 2 to 6 and R 8 is a chain hydrocarbon) And monoesters of fatty acid with C 2 -C 6 glycol.
  • ester of C 2 to C 6 glycol and fatty acid as the fatty acid to be esterified (corresponding to R 8 COOH and R 9 COOH in the formula (8) and the formula (9)), C 2 to C 6 glycol
  • ester of fatty acid with the fatty acid provided that it satisfies the requirements of the above IOB, melting point and water solubility, for example, "ester of (a 1 ) chain hydrocarbon tetraol with at least one fatty acid"
  • the ester of a C 2 ⁇ C 6 glycols and fatty acid in view of the potential for degradation by oxidation and the like, derived from saturated fatty acids, esters of C 2 ⁇ C 6 glycols and fatty acid, Nachi Suwa, C 2 It is preferably an ester of a -C 6 glycol and a saturated fatty acid.
  • ester of C 2 -C 6 glycol and fatty acid an ester of glycol and fatty acid derived from glycol having a large number of carbon atoms, for example, butylene glycol, in order to make IOB small and make it more hydrophobic. It is preferable that it is an ester of a glycol derived from pentylene glycol or hexylene glycol and a fatty acid.
  • ester of C 2 -C 6 glycol and fatty acid a diester is preferable in order to make IOB small and to make it more hydrophobic.
  • examples of commercial products of the ester of C 2 -C 6 glycol and fatty acid include Commol BL, Commol BS (manufactured by NOF Corporation) and the like.
  • (B) a compound having a chain hydrocarbon moiety and 2 to 4 hydroxyl groups replacing the hydrogen atom of the chain hydrocarbon moiety, (B2) a chain hydrocarbon moiety, and Ether with compound having one hydroxyl group replacing hydrogen atom of linear hydrocarbon moiety
  • (B) A compound having (B1) a chain hydrocarbon moiety and 2 to 4 hydroxyl groups replacing the hydrogen atom of the chain hydrocarbon moiety, (B2) a chain hydrocarbon moiety, and the above chain Ether with a compound having one hydroxyl group replacing hydrogen atoms in the cyclic hydrocarbon moiety (hereinafter sometimes referred to as “compound (B)”) has the above-mentioned IOB, melting point and water solubility And all hydroxyl groups may not be etherified.
  • Examples of the compound having (B1) a chain hydrocarbon portion and 2 to 4 hydroxyl groups replacing the hydrogen atoms of the above chain hydrocarbon portion are listed as the compound (A1) in the “compound (A)”.
  • Examples of (B2) a compound having a linear hydrocarbon moiety and one hydroxyl group replacing the hydrogen atom of the linear hydrocarbon moiety include, for example, A compound in which one hydrogen atom of hydrocarbon is substituted with one hydroxyl group (—OH), for example, aliphatic monohydric alcohol such as saturated aliphatic monohydric alcohol and unsaturated aliphatic monohydric alcohol Can be mentioned.
  • saturated aliphatic monohydric alcohol for example, a C 1 to C 20 saturated aliphatic monohydric alcohol, for example, methyl alcohol (C 1 ) (C 1 represents a carbon number, the same applies hereinafter), ethyl alcohol C 2 ), propyl alcohol (C 3 ) and its isomers, such as isopropyl alcohol (C 3 ), butyl alcohol (C 4 ) and its isomers, such as sec-butyl alcohol (C 4 ) and tert-butyl alcohol (C 4 ), pentyl alcohol (C 5 ), hexyl alcohol (C 6 ), heptyl alcohol (C 7 ), octyl alcohol (C 8 ) and isomers thereof, such as 2-ethylhexyl alcohol (C 8 ), nonyl alcohol (C 9 ), decyl alcohol (C 10 ), dodecyl alcohol (C 12 ), tetradecyl al Call (C 14), hexadect
  • an ether of (b 1 ) chain hydrocarbon tetraol and at least one aliphatic monohydric alcohol for example, monoether, diether, triether and tetraether, preferably diether, triether Ethers and tetraethers, more preferably triethers and tetraethers, and even more preferably tetraethers, ethers of (b 2 ) chain hydrocarbon triols and at least one aliphatic monohydric alcohol, such as monoethers, diethers and the like triether, preferably diethers and triethers and more preferably tri-ether, and (b 3) a chain hydrocarbon diol and at least one aliphatic monohydric ether alcohols, for example, mono- and diethers and, Mashiku diethers.
  • Examples of the ether of the above linear hydrocarbon tetraol and at least one aliphatic monohydric alcohol include the following formulas (10) to (13): (Wherein, each of R 10 to R 13 is a chain hydrocarbon). And tetraethers of pentaerythritol and aliphatic monohydric alcohols, triethers, diethers and monoethers.
  • Examples of the ether of the above linear hydrocarbon triol and at least one aliphatic monohydric alcohol include the following formulas (14) to (16): (Wherein, R 14 to R 16 are each a chain hydrocarbon). And triethers of glycerol and aliphatic monohydric alcohols, diethers and monoethers.
  • R 17 OC n H 2n OR 18 (Wherein n is an integer of 2 to 6 and R 17 and R 18 are each a chain hydrocarbon) Diethers of C 2 -C 6 glycols and aliphatic monohydric alcohols, and the following formula (18): R 17 OC n H 2n OH (18) (Wherein n is an integer of 2 to 6 and R 17 is a chain hydrocarbon) And monoethers of C 2 -C 6 glycols and aliphatic monohydric alcohols.
  • the total carbon number of aliphatic monohydric alcohol constituting the tetraether of pentaerythritol and aliphatic monohydric alcohol that is, in the above formula (10)
  • the IOB is 0.44. Therefore, in the above tetraether of pentaerythritol and aliphatic monohydric alcohol, IOB is required to be about 0.00 to about 0.60 when the total carbon number of aliphatic monohydric alcohol is about 4 or more. Fulfill.
  • the total carbon number of aliphatic monohydric alcohol constituting triether of pentaerythritol and aliphatic monohydric alcohol ie, in the above formula (11)
  • the IOB is 0.57. Therefore, in the above triether of pentaerythritol and aliphatic monohydric alcohol, IOB is required to be about 0.00 to about 0.60 when the total carbon number of aliphatic monohydric alcohol is about 9 or more. Fulfill.
  • the total carbon number of aliphatic monohydric alcohols constituting the diether of pentaerythritol and aliphatic monohydric alcohol that is, R 10 in the above formula (12)
  • the IOB is 0.60 when the sum of the carbon numbers of the and R 11 moieties is 15. Therefore, in the diether of pentaerythritol and aliphatic monohydric alcohol, IOB satisfies the requirement of about 0.00 to about 0.60 when the total carbon number of aliphatic monohydric alcohol is about 15 or more. .
  • the carbon number of the aliphatic monohydric alcohol constituting the monoether of pentaerythritol and aliphatic monohydric alcohol that is, R 10 in the above formula (13)
  • the IOB is 0.59. Therefore, in the monoether of pentaerythritol and aliphatic monohydric alcohol, the IOB satisfies the requirement of about 0.00 to about 0.60 when the carbon number of the aliphatic monohydric alcohol is about 22 or more.
  • the total carbon number of aliphatic monohydric alcohol constituting triether of glycerin and aliphatic monohydric alcohol that is, R in the formula (14)
  • the IOB is 0.50. Therefore, in the above triether of glycerin and aliphatic monohydric alcohol, IOB satisfies the requirement of about 0.00 to about 0.60 when the total carbon number of aliphatic monohydric alcohol is about 3 or more. .
  • the total carbon number of aliphatic monohydric alcohols constituting the diether of glycerin and an aliphatic monohydric alcohol that is, in the formula (15), R 14 and R 15
  • the IOB is 0.58. Therefore, in the diether of glycerin and an aliphatic monohydric alcohol, the IOB satisfies the requirement of about 0.00 to about 0.60 when the total carbon number of the aliphatic monohydric alcohol is about 9 or more.
  • the carbon number of the aliphatic monohydric alcohol constituting the monoether of glycerin and aliphatic monohydric alcohol that is, the carbon of R 14 in the formula (16)
  • the IOB is 0.58. Therefore, in the monoether of glycerin and aliphatic monohydric alcohol, the IOB satisfies the requirement of about 0.00 to about 0.60 when the carbon number of the aliphatic monohydric alcohol is about 16 or more.
  • the compound (B) can be produced by dehydration condensation of the compound (B1) and the compound (B2) in the presence of an acid catalyst.
  • compound C1 a linear hydrocarbon moiety and a carboxylic acid, a hydroxy acid, an alkoxy acid or an oxo acid containing 2 to 4 carboxyl groups replacing the hydrogen atom of the linear hydrocarbon moiety
  • compound C1 may be, for example, a linear hydrocarbon carboxylic acid having 2 to 4 carboxyl groups, such as a linear hydrocarbon dicarboxylic acid, such as an alkane dicarboxylic acid, such as ethanedioic acid.
  • a linear hydrocarbon hydroxy acid having 2 to 4 carboxyl groups for example, a linear chain having 2 to 4 carboxyl groups, such as malic acid, tartaric acid, citric acid, isocitric acid, etc.
  • Hydrocarbon alkoxy acids such as O-acetyl citric acid, and linear hydrocarbon oxo acids having 2 to 4 carboxyl groups are included.
  • Examples of the compound having a (C2) linear hydrocarbon moiety and one hydroxyl group replacing the hydrogen atom of the linear hydrocarbon moiety include those listed in the “compound (B)”, for example, Aliphatic monohydric alcohols are mentioned.
  • an ester of a linear hydrocarbon tetracarboxylic acid having 4 carboxyl groups (c 1 ), a hydroxy acid, an alkoxy acid or an oxo acid, and at least one aliphatic monohydric alcohol for example, Mono-, di-, tri- and tetra-esters, preferably diesters, tri- and tetra-esters, more preferably tri- and tetra-esters, and still more preferably tetra-esters, chained with 3 (c 2 ) carboxyl groups
  • Esters of hydrocarbon tricarboxylic acids, hydroxy acids, alkoxy acids or oxo acids with at least one aliphatic monohydric alcohol such as monoesters, diesters and triesters, preferably diesters and triesters, and more preferably triesters Ester
  • aliphatic monohydric alcohol constituting the above ether corresponding to R 19 OH and R 20 OH in the formula (19)
  • the above ether satisfies the requirements of the above IOB, melting point and water solubility It is not particularly limited, and examples thereof include aliphatic monohydric alcohols listed in the “compound (B)” section.
  • the total carbon number of the aliphatic monohydric alcohol constituting the ether that is, the carbon number of the R 19 and R 20 moieties in the above formula (19) Since the IOB is 0.50 when the sum of the two is 2, the requirement of the above IOB is satisfied if the total carbon number is about 2 or more. However, when the total carbon number is about 6, the water solubility is as high as about 2 g, and there is also a problem from the viewpoint of the vapor pressure. In order to satisfy the requirement of water solubility of about 0.00 to about 0.05 g, the total carbon number is preferably about 8 or more.
  • dialkyl ketone [(D 2 ) dialkyl ketone]
  • dialkyl ketone following Formula (20): R 21 COR 22 (20) (Wherein, each of R 21 and R 22 is an alkyl group) And compounds having the formula:
  • the total carbon number is preferably about 8 or more. Also, in consideration of the vapor pressure, the carbon number is preferably about 10 or more, and preferably about 12 or more.
  • the melting point is about ⁇ 50 ° C.
  • the vapor pressure is about 230 Pa at 20 ° C.
  • the above-mentioned dialkyl ketone is commercially available and can be obtained by a known method, for example, oxidation of a secondary alcohol with chromic acid or the like.
  • Examples of the fatty acid (corresponding to R 23 COOH in the formula (21)) constituting the above-mentioned ester are listed, for example, in “ester of (a 1 ) chain hydrocarbon tetraol with at least one fatty acid”.
  • a fatty acid that is, a saturated fatty acid or an unsaturated fatty acid is mentioned, and considering the possibility of modification by oxidation etc., a saturated fatty acid is preferred.
  • the aliphatic monohydric alcohol (corresponding to R 24 OH in the formula (21)) constituting the above-mentioned ester include, for example, aliphatic monohydric alcohols listed in the “compound (B)” section.
  • the sum of carbon number of fatty acid and aliphatic monohydric alcohol that is, the sum of carbon number of R 23 C and R 24 in the formula (21) is 5
  • the IOB is 0.60
  • the requirements of the above IOB are satisfied when the total carbon number of the R 23 C and R 24 moieties is about 5 or more.
  • the vapor pressure is as high as 2,000 Pa or more. Therefore, in consideration of the vapor pressure, the total carbon number is preferably about 12 or more. If the total carbon number is about 11 or more, the water solubility can satisfy the requirement of about 0.00 to about 0.05 g.
  • esters of the above fatty acids with aliphatic monohydric alcohols include, for example, esters of dodecanoic acid (C 12 ), dodecyl alcohol (C 12 ), tetradecanoic acid (C 14 ), and dodecyl alcohol (C 12 )
  • esters of fatty acids and aliphatic monohydric alcohols include Electol WE 20 and Electol WE 40 (all manufactured by NOF Corporation).
  • the total carbon number of R 25 and R 26 is preferably about 7 or more, and more preferably about 9 or more.
  • the above dialkyl carbonate is commercially available, and can be synthesized by the reaction of phosgene with alcohol, the reaction of formic acid chloride ester with alcohol or alcoholate, and the reaction of silver carbonate with alkyl iodide.
  • Examples of the above-mentioned polyoxy C 2 -C 6 alkylene glycol or ester or ether thereof include (e 1 ) polyoxy C 2 -C 6 alkylene glycol, (e 2 ) polyoxy C An ester of a 2 to C 6 alkylene glycol with at least one fatty acid, an ether of (e 3 ) polyoxy C 2 to C 6 alkylene glycol and at least one aliphatic monohydric alcohol, (e 4 ) polyoxy C 2 to C 6 An ester of an alkylene glycol with a linear hydrocarbon tetracarboxylic acid, a linear hydrocarbon tricarboxylic acid, or a linear hydrocarbon dicarboxylic acid, and (e 5 ) polyoxy C 2 -C 6 alkylene glycol, with a linear hydrocarbon tetra And ethers with linear hydro
  • oxy C 2 ⁇ C 6 alkylene backbone from the viewpoint of lowering the polyoxy C 2 ⁇ C 6 IOB of alkylene glycols, polyoxypropylene skeleton, oxybutylene skeleton, it is oxypentylene skeleton, or an oxy hexylene skeleton preferably More preferably, they are an oxybutylene skeleton, an oxypentylene skeleton, or an oxyhexylene skeleton.
  • the above polyoxy C 2 -C 6 alkylene glycol has the following formula (23): HO- (C m H 2m O) n -H (23) (In the formula, m is an integer of 2 to 6) Can be represented by
  • homopolymers of formula (23) may include homopolymers of propylene glycol, butylene glycol, pentylene glycol or hexylene glycol. From the above, in the formula (23), m is about 3 to about 6, and more preferably about 4 to about 6, and n is 2 or more.
  • n the poly C 2 -C 6 alkylene glycol has an IOB of about 0.00 to about 0.60, a melting point of about 45 ° C. or less, and 100 g of water at 25 ° C. It is a value that has a water solubility of about 0.00 to about 0.05 g.
  • the weight average molecular weight of the polyoxy C 2 -C 6 alkylene glycol is preferably about 200 to about 10,000, more preferably about 250 to about 8,000, and more preferably It is in the range of about 250 to about 5,000.
  • the weight average molecular weight of the poly C 3 alkylene glycol, ie, polypropylene glycol is preferably about 1,000 to about 10,000, more preferably about 3,000 to about 8 And more preferably in the range of about 4,000 to about 5,000.
  • the weight average molecular weight is less than about 1,000, the water solubility does not satisfy the requirements, and the larger the weight average molecular weight, the more the absorber transfer rate and the top sheet whiteness tend to be improved.
  • Examples of commercial products of polyoxy C 2 ⁇ C 6 alkylene glycol e.g., UNIOL (TM) D-1000, D-1200 , D-2000, D-3000, D-4000, PB-500, PB-700, PB -1000 and PB-2000 (manufactured by NOF Corporation).
  • UNIOL TM
  • D-1000, D-1200 , D-2000, D-3000, D-4000, PB-500, PB-700, PB -1000 and PB-2000 manufactured by NOF Corporation.
  • ester of (e 2 ) polyoxy C 2 -C 6 alkylene glycol with at least one fatty acid is the OH terminal of the polyoxy C 2 to C 6 alkylene glycol described in the section “(e 1 ) polyoxy C 2 to C 6 alkylene glycol”.
  • fatty acids ie, monoesters and diesters.
  • the fatty acid to be esterified is, for example, listed in “ester of (a 1 ) chain hydrocarbon tetraol and at least one fatty acid”.
  • Fatty acids that is, saturated fatty acids or unsaturated fatty acids, and in view of the possibility of modification by oxidation etc., saturated fatty acids are preferred.
  • Examples of commercially available esters of the polyoxy C 2 -C 6 alkylene glycol and fatty acid include Wilbright cp 9 (manufactured by NOF Corporation).
  • aliphatic monohydric alcohols to be etherified in the ether of polyoxy C 2 -C 6 alkylene glycol and at least one aliphatic monohydric alcohol include, for example, aliphatics listed in the “compound (B)” section. Monohydric alcohol is mentioned.
  • esters of the above polyoxy C 2 -C 6 alkylene glycol with chain hydrocarbon tetracarboxylic acid, chain hydrocarbon tricarboxylic acid, or chain hydrocarbon dicarboxylic acid are commercially available, and chain hydrocarbon tetracarbons are also commercially available. It can be produced by polycondensation of C 2 -C 6 alkylene glycol with an acid, linear hydrocarbon tricarboxylic acid or linear hydrocarbon dicarboxylic acid under known conditions.
  • chain hydrocarbon tetraol to be etherified the chain hydrocarbon triol, and the chain hydrocarbon diol, those described in the “compound (A)” section, for example, pentaerythritol, glycerin and glycol Can be mentioned.
  • ethers of the above polyoxy C 2 -C 6 alkylene glycol and chain hydrocarbon tetraol, chain hydrocarbon triol, or chain hydrocarbon diol are, for example, UnilobeTM 5TP-300 KB, and Uniol (trademark) TG-3000 and TG-4000 (made by NOF Corporation) can be mentioned.
  • Unilube (TM) 5TP-300KB is a compound obtained by polycondensation of 65 moles of propylene glycol and 5 moles of ethylene glycol with 1 mole of pentaerythritol, and its IOB is 0.39, and the melting point is less than 45 ° C. And the water solubility was less than 0.05 g.
  • Uniol (TM) TG-3000 is a compound obtained by polycondensing 50 moles of propylene glycol with 1 mole of glycerin, its IOB is 0.42, its melting point is less than 45 ° C, and its water solubility is 0.05 g And the weight average molecular weight was about 3,000.
  • Uniol (TM) TG-4000 is a compound obtained by polycondensing 70 moles of propylene glycol with 1 mole of glycerin, its IOB is 0.40, melting point is less than 45 ° C., and water solubility is 0.05 g And the weight average molecular weight was about 4,000.
  • the ether of the polyoxy C 2 -C 6 alkylene glycol and the chain hydrocarbon tetraol, chain hydrocarbon triol or chain hydrocarbon diol is also a chain hydrocarbon tetraol, chain hydrocarbon triol or It can be produced by adding a C 2 -C 6 alkylene oxide to a linear hydrocarbon diol under known conditions.
  • the chain hydrocarbon has an IOB of 0.00 and an aqueous solubility of almost 0 g because the inorganic value is 0, and the blood has a melting point of about 45 ° C. or less. It may be included in the modifier.
  • Examples of the chain hydrocarbon include (f 1 ) chain alkanes such as straight chain alkanes and branched chain alkanes, and in the case of straight chain alkanes, for example, the melting point is about 45 ° C. or less In general, those containing 22 or less carbon atoms are included. Also, in consideration of the vapor pressure, those having 13 or more carbon atoms are generally included.
  • the blood modifying agent has been found to at least have the effect of reducing blood viscosity and surface tension. Since the menstrual blood to be absorbed by the absorbent article contains proteins such as the endometrial wall as compared with normal blood, they act to connect the blood cells to each other, and the blood cells are in a continuous state. Cheap. Therefore, the menstrual blood to be absorbed by the absorbent article tends to have a high viscosity, and when the top sheet is a non-woven fabric or a woven fabric, menstrual blood tends to be clogged between fibers, and the wearer feels sticky. And it spreads and leaks on the surface of the top sheet.
  • a blood modifying agent having an IOB of about 0.00 to about 0.60 is highly organic and easily enters between blood cells, thereby stabilizing the blood cells and making it difficult for the blood cells to form a continuous structure. It is thought that can be done. It is considered that the absorber makes it easy to absorb menstrual blood by stabilizing the blood cells and making the blood cells less likely to form a continuous structure.
  • the so-called SAP when menstrual blood is absorbed, blood cells that have undergone continuous change cover the SAP surface, making it difficult for the SAP to exhibit its absorption performance.
  • SAP By stabilizing blood cells, it is considered that SAP can more easily exhibit absorption performance.
  • the blood modifying agent having high affinity for red blood cells protects the red blood cell membrane, so that the red blood cells are less likely to be destroyed.
  • FIG. 7 is a figure for demonstrating the absorbent article manufacturing apparatus 100 used for the manufacturing method of the absorbent article 1 in one Embodiment of this invention.
  • a process of forming an absorbent a process of preparing a sheet for top sheet, a process of forming compressed grooves in a laminate, a process of preparing a sheet for back sheet, a continuum of absorbent articles Cutting and applying a blood modifying agent to the absorbent article.
  • the top sheet sheet used in the step of preparing the top sheet sheet includes a process of preparing the resin film sheet, a process of forming the recess in the resin film sheet, and a process of gear stretching the resin film sheet. It is manufactured by the manufacturing method of the seat for sheets.
  • the absorber 128 is formed on the belt 110.
  • Pulverized pulp 122 is supplied to the pattern drum 120 from a pulverized pulp supply device (not shown).
  • a recess 124 is formed on the outer peripheral portion of the pattern drum 120 as a mold for packing crushed pulp.
  • the inside of the pattern drum 120 is suctioned 126, and the crushed pulp 122 supplied to the pattern drum 120 is sucked into the recess 124 and compressed. Then, the pulp 122 compressed in the recess 124 is formed into the absorber 128.
  • the absorber 128 is placed on the belt.
  • the top sheet 216 produced by the method for producing a top sheet described later is disposed on the absorber 128 and the top sheet 216 is adhered to the absorber 128. .
  • the emboss device 130 is used to form the squeezed grooves in the laminate 262 of the top sheet 216 and the absorber 128.
  • the laminate 262 passes between the upper roll 131 and the lower roll 132 of the embossing device 130.
  • On the surface of the outer periphery of the upper roll 131 a convex portion (not shown) having a shape corresponding to the pressing groove 7 of the absorbent article 1 shown in FIG. 1 is provided.
  • the lower roll 132 is a plain roll whose outer peripheral surface is smooth.
  • the portion of the laminate 262 corresponding to the compressed grooves 7 of the absorbent article 1 shown in FIG. 1 is in the thickness direction And compressed grooves are formed in the laminate 262.
  • an adhesive is applied to the sheet 142 for back sheet supplied from the sheet roll 140 for back sheet using an application device (not shown), and then lamination is performed in which compressed grooves are formed. It adheres to the surface on the opposite side to the sheet
  • the cutter 150 is used to cut the continuum 144 of the absorbent article into the shape of the absorbent article to produce the absorbent article.
  • the above-described blood modifying agent 161 is applied to the central region of the absorbent article using a modifier applying spray 160 to apply blood to the surface of the top sheet. Form a modifier layer.
  • the blood modifying agent 161 applied to the central region of the absorbent article may be applied to at least a portion facing the outlet of the wearer's body fluid.
  • the length in the lengthwise direction is preferably 50 mm or more, more preferably 10 mm or more
  • the length in the width direction is preferably 10 mm or more, more preferably 30 mm or more, centering on the center of the absorbent article.
  • a blood modifying agent may be applied to an area.
  • the blood modifying agent was applied after the step of cutting the continuum of the absorbent article, the blood modifying agent may be applied in the step of producing the top sheet described later.
  • the downstream stage of the manufacturing process of the absorbent article for example, the blood just before packaging the absorbent article It is preferred to apply the modifier to the absorbent article.
  • the method of manufacturing the absorbent article 1 includes a step of forming an adhesive portion on the continuous body 144 of the absorbent article, a step of forming a seal portion on the continuous body 144 of the absorbent article, and the like.
  • the resin film sheet 212 supplied from the roll 210 of the resin film sheet is supplied to the recess forming roll 220.
  • the resin film sheet 212 is made to pass the recessed part formation roll 220, and the resin film sheet 214 (refer FIG. 9) in which the recessed part 2141 was formed is produced.
  • the recess forming roll 220 comprises a knurling roll 221 and a preheating roll 222 having a smooth surface.
  • FIGS. 8A and 8B show an example of the knurled roll 221.
  • FIG. FIG. 8A is a view showing the entire knurled roll 221
  • FIG. 8B is an enlarged view of a portion 223 having unevenness on the outer peripheral surface of the knurled roll 221.
  • FIG. 8C shows an example of the preheating roll 222 having a smooth surface.
  • a grid-like convex portion 224 is provided on the surface 223 of the knurled roll 221.
  • a rhombus recess 225 is formed on the surface of the knurled roll 221.
  • the shape of the recessed part 225 of the knurl roll 221 is not limited to a rhombus, You may be shapes, such as a square, a rectangle, a parallelogram, a trapezoid, a triangle, and a hexagon.
  • the center line spacing of the convex parts 224 arranged in parallel in the lattice-like convex parts 224 is preferably 0.2 mm or more and 10 mm or less, more preferably 0.4 mm or more and 2 mm It is below.
  • the pitch of the grid-like convex portions 224 is less than 0.2 mm or greater than 10 mm, the concave portion may not be formed in the resin film.
  • the width of the grid-like convex portion 224 is preferably 0.01 mm or more and 1 mm or less, and more preferably 0.03 mm or more and 0.1 or less.
  • the length of one side of the rhombic recess 225 is preferably 0.1 mm or more and 5 mm or less, and more preferably 0.2 mm or more and 1 mm or less.
  • the width of the grid-like convex part 224 is less than 0.01 mm or more than 1 mm, or when the length of one side of the rhombus concave part 225 is less than 0.1 mm or more than 5 mm, the concave part may not be formed in the resin film. .
  • the preheated roll 222 having a smooth surface is maintained at a temperature of 70 ° C. or more and 100 ° C. or less, and heats the supplied resin film sheet 212. Thereby, the resin film sheet 212 becomes soft and easy to form.
  • the resin film sheet 212 passes between the knurled roll 221 and the roll 222 having a smooth surface, the resin film sheet 212 receives a strong pressure in the thickness direction in a portion in contact with the grid-like convex portion 224. Thereby, as shown in FIG. 9, the fine recessed part 2141 is formed in the resin film sheet 214. As shown in FIG. In fact, the number of recesses 2141 formed in the resin film sheet 212 is smaller than that shown in FIG. 9, and the number of recesses 2141 per unit area is also much larger than that shown in FIG.
  • the concave portion 2141 is formed only in the range 2143 corresponding to the area 12 (see FIG. 1) in the resin film sheet 214 where the absorber 4 of the absorbent article 1 is provided. Here, the range corresponding to the absorbent article 1 in the resin film sheet 214 is the range indicated by the dotted line 2142.
  • the first ridge portion, the second ridge portion, and the second ridge portion of the top sheet 2 are caused to pass through the resin film sheet 214 having the recess formed in the stretching gear roll 230 shown in FIG.
  • the bottom is formed in a resin film sheet 214.
  • symbol 216 is a resin film sheet which formed the 1st protrusion part, the 2nd protrusion part, and the bottom part.
  • the drawing gear roll 230 includes an upper roll 231 and a lower roll 232.
  • 10 (a) is a view for explaining the upper roll 231 of the drawing gear roll 230
  • FIG. 10 (b) is a view for explaining the gear teeth 233 arranged on the outer peripheral surface of the upper roll 231.
  • 10 (c) is a cross-sectional view taken along the line BB in FIG. 10 (b).
  • the gear teeth 233 extend discontinuously in the circumferential direction of the upper roll 231. That is, the gear teeth 233 extending in the circumferential direction of the upper roll 231 are interrupted at multiple points along the way.
  • a second protrusion portion is formed on the resin film sheet 214 by the portion 234 where the gear teeth 233 are disconnected.
  • the width of gear teeth 233 is, for example, 0.3 mm or more and 0.5 mm or less, and the distance between the centers of adjacent gear teeth 233 is, for example, 1.0 mm or more and 1.2 mm or less.
  • FIG. 11 (a) is a view for explaining the lower roll 232 of the drawing gear roll 230
  • FIG. 11 (b) is a view for explaining the gear teeth 235 disposed on the outer peripheral surface of the lower roll 232
  • FIG. 11C is a cross-sectional view taken along the line CC of FIG.
  • the gear teeth 235 extend in the circumferential direction of the lower roll 232.
  • the lower roll 232 is not interrupted at multiple points along the way.
  • the width of the gear teeth 235 is, for example, equal to the width of the gear teeth 233 of the upper roll 231, and the distance between the centers of adjacent gear teeth 235 is, for example, equal to the distance between the centers of the gear teeth 233 of the upper roll 231.
  • the radial length of the upper roll 231 at the portion where the gear teeth 233 of the upper roll 231 and the gear teeth 235 of the lower roll 232 are engaged, that is, the biting depth is, for example, 1.25 mm.
  • the gap between the gear teeth 233 of the upper roll 231 and the gear teeth 235 of the lower roll 232 when the gear teeth 233 of the upper roll 231 and the gear teeth 235 of the lower roll 232 are engaged is, for example, 0.25 mm or more , 0.45 mm or less.
  • the resin film sheet 214 passes through the drawing gear roll 230, the resin film 214 is bent in a substantially wave shape, and the resin film 214 forms the first ridge 21 and the second ridge of the top sheet 2.
  • the portion 22 is formed.
  • an opening 25 (see FIG. 4) of the top sheet 2 is further formed in the region 2143 (see FIG. 9) in which the recess 2141 of the resin film sheet 214 is formed.
  • the resin film sheet 214 is largely drawn at a portion 236 where the gear teeth 233 of the upper roll 231 and the gear teeth 235 of the lower roll 232 are engaged.
  • the resin film sheet 214 is thin at the part where the concave part 2141 (see FIG. 9) is formed in the above-mentioned concave part forming step, and the part where the scratch is given by the grid-like convex part 224 of the knurling roll 221 As it is present, the strength is weak, and the recess 2141 of the resin film sheet 214 breaks when it is stretched.
  • the concave portion 2141 of the resin film sheet 214 is torn, the torn portion of the resin film sheet 214 is spread, and the opening portion is to the torn portion of the resin film sheet 214. It is formed.
  • the resin film sheet 214 is not stretched much at the portions 237 and 238 where the gear teeth 233 of the upper roll 231 and the gear teeth 235 of the lower roll 232 are not engaged. For this reason, in the portions 237 and 238 in which the gear teeth 233 of the upper roll 231 and the gear teeth 235 of the lower roll 232 in the resin film sheet 241 are not engaged, the resin film sheet 214 described above The recess 2141 formed in the recess forming step is not broken and does not become an opening.
  • the absorbent article 1 according to the embodiment of the present invention described above can be modified as follows.
  • the absorbent article may not have a wing. That is, the absorbent article may be only the main body.
  • an adhesive part is provided on the clothes-side surface of the main body part so that the absorbent article can be fixed to the underwear even without the wing part.
  • the first channel and the second channel can be formed by the first ridge of the top sheet and the back It is not limited to the flow path constituted of the sheet and the flow path constituted of the second ridge portion of the top sheet and the back sheet.
  • a resin layer is formed in a region between the top sheet and the back sheet outside the widthwise edges of the absorber in the main body, except for the portion corresponding to the flow path, by a method such as printing. It is also good.
  • the portion where the resin layer is not formed is hollow between the top sheet and the back sheet, so that portion can be used as a flow path for pouring in the body fluid that has leaked from the absorber.
  • the first channel 21 and the second channel 22 may be formed in the top sheet 2, and the first sheet and the second channel may not be formed in the top sheet 2 of the wing portion 5. Also in this case, when pressure is applied to the absorbent article 1, it is possible to suppress leakage of the body fluid exuded from the absorbent body 4 from the width direction of the absorbent article 1.
  • the first protrusion is formed at least outside the both edges in the width direction of the absorber.
  • the strip 21, the second protrusion 22 and the bottom 23 may be formed on the side sheet 18A, and the bottom 23 of the side sheet 18A may be joined to the back sheet.
  • the top sheet 2A may be a non-woven fabric. Even when the top sheet 2A is a non-woven fabric, it is possible to easily fold the wing portion of the absorbent article in accordance with the shape of the edge of the leg opening of the undergarment.
  • the non-woven fabric used for the top sheet 2A may be natural fibers or chemical fibers. Natural fibers used for the top sheet 2A include cellulose such as crushed pulp and cotton. Chemical fibers used for the top sheet 2A include regenerated cellulose such as rayon and fibril rayon, semi-synthetic cellulose such as acetate and triacetate, thermoplastic hydrophobic chemical fiber, and thermoplastic hydrophobic chemical fiber subjected to hydrophilization treatment, etc. It can be mentioned.
  • thermoplastic hydrophobic chemical fibers used for the top sheet 2A include single fibers such as polyethylene (PE), polypropylene (PP) and polyethylene terephthalate (PET), fibers obtained by graft polymerization of polyethylene and polypropylene, and core-sheath structures, etc. Composite fibers are mentioned.
  • the top sheet 2A may be provided with the first protrusion, the second protrusion, and the bottom.
  • first ridge, the second ridge, and the bottom can be formed on the top sheet or the side sheet at least on the outer sides of both edges in the width direction of the absorber, an absorber on the top sheet is provided.
  • the first protrusion, the second protrusion, and the bottom may or may not be formed in the area being covered.
  • the first ridge 21B of the top sheet 2B is curved so as to protrude outward in the width direction at least outside the both edges 41B in the width direction of the absorber 4B. It is also good.
  • the body fluid 31B which has flowed in the longitudinal direction (Y direction) in the flow path constituted by the first ridge 21B and the back sheet, and which is exuded from the absorber 4B is absorbed again by the absorber 4B. . And it can further suppress that the bodily fluid 31B which exudes from the absorber 4B by applying pressure to an absorbent article leaks from the width direction of an absorbent article.
  • the edge 41B in the width direction of the absorber 4B is not curved so as to protrude inward in the width direction (X direction)
  • the flow path formed of the first protrusion 21B and the back sheet The body fluid 31B that flows from the absorber 4B and flows in the longitudinal direction (Y direction) is absorbed by the absorber 4B again.
  • the blood modifying agent since the blood modifying agent has a mechanism to lower the viscosity and surface tension of the blood, the body fluid is transferred to the absorber 4 without remaining on the top sheet 2 by the blood modifying layer 24 and absorbed. 4 can be absorbed.
  • the following examples confirmed that the blood modifying agent has a mechanism to lower the viscosity and surface tension of blood. This check was performed using a non-woven fabric in which the body fluid tends to remain as compared to the resin film.
  • the sanitary napkin comprises a top sheet formed of an air through non-woven fabric (composite fiber of polyester and polyethylene terephthalate, basis weight: 35 g / m 2 ) treated with a hydrophilic agent, and a composite of air through non-woven fabric (polyester and polyethylene terephthalate) Fiber, second sheet formed of basis weight: 30 g / m 2 ), pulp (basis weight: 150 to 450 g / m 2 , more in the central part), acrylic high absorption polymer (basis weight: 15 g / m 2 ) And, it was formed from an absorbent including a tissue as a core wrap, a water repellent treated side sheet, and a back sheet made of polyethylene film.
  • an absorbent including a tissue as a core wrap, a water repellent treated side sheet, and a back sheet made of polyethylene film.
  • Triethylene CL oil fatty acid glycerides, manufactured by NOF Corporation C 8 fatty acid: fatty acid of C 12 is approximately included in a weight ratio of 44:56, triesters of glycerin and fatty acid, the weight average molecular weight: about 570
  • -Panaceto 800 B manufactured by NOF Corporation Triester of glycerin and fatty acid in which all fatty acids are 2-ethylhexanoic acid (C 8 ), weight average molecular weight: about 470 NA36, manufactured by NOF Corporation C 16 fatty acids: C 18 fatty acids: C 20 fatty acids (including both saturated fatty acids and unsaturated fatty acids) in a weight ratio of approximately 5: 92: 3, Triester of glycerin and fatty acid, weight average molecular weight: about 880
  • Tricot oil fatty acid glyceride manufactured by NOF Corporation C 8 fatty acid: C 10 fatty acid: C 12 fatty acid: C 14 fatty acid: C 16 fatty acid (including both saturated fatty acid and unsaturated fatty acid) is approximately 4 Triester of glycerin and fatty acid, contained in a weight ratio of 8: 60: 25: 3, weight average molecular weight: 670 ⁇ Caprylic diglyceride, manufactured by NOF Corporation Diester of glycerin and fatty acid wherein fatty acid is octanoic acid, weight average molecular weight: 340
  • Uniol D-4000 polypropylene glycol manufactured by NOF Corporation, weight average molecular weight: about 4,000 Uniol PB500, polybutylene glycol manufactured by NOF Corporation, weight average molecular weight: about 500 Uniol PB700, manufactured by NOF Corporation, polyoxybutylene polyoxypropylene glycol, weight average molecular weight: about 700
  • Uniol PB 1000 R polybutylene glycol manufactured by NOF Corporation, weight average molecular weight: about 1000 [Ester of (e 2 ) polyoxy C 2 -C 6 alkylene glycol with at least one fatty acid] ⁇ Wilbright cp 9, a compound in which OH groups at both ends of polybutylene glycol manufactured by NOF Corporation were esterified with hexadecanoic acid (C 16 ), weight average molecular weight: about 1,150
  • UNIOL TG-3000 glyceryl ether of polypropylene glycol manufactured by NOF Corporation, about 16 repeating units, weight average molecular weight: about 3,000 ⁇ UNIOL TG-4000, glyceryl ether of polypropylene glycol manufactured by NOF Corporation, about 16 repeating units, weight average molecular weight: about 4,000
  • -PEG 1500 polyethylene glycol manufactured by NOF Corporation, weight average molecular weight: about 1,500 to about 1,600 Nonion S-6, manufactured by NOF Corporation, polyoxyethylene monostearate, repeating unit of about 7 weight average molecular weight: about 880 Will Bright s 753, manufactured by NOF Corporation polyoxyethylene polyoxypropylene polyoxybutylene glycerin, weight average molecular weight: about 960
  • TG-330 a glyceryl ether of polypropylene glycol manufactured by NOF Corporation, about 6 repeating units, weight average molecular weight: about 330 ⁇ UNIOL TG-1000, glyceryl ether of polypropylene glycol manufactured by NOF Corporation, about 16 repeating units, weight average molecular weight: about 1,000
  • Unirube DGP-700 a diglyceryl ether of polypropylene glycol manufactured by NOF Corporation, about 9 repeating units, weight average molecular weight: about 700 -Uniox HC60, manufactured by NOF Co., Ltd. polyoxyethylene hydrogenated castor oil, weight average molecular weight: about 3,570 ⁇ Vaseline, Cognis Japan Ltd. Petroleum derived hydrocarbon, semi-solid
  • the IOB, melting point and water solubility of the above sample are shown in Table 2 below.
  • the water solubility was measured according to the above-mentioned method, but 20.0 g was added to 100 g of demineralized water, and a sample dissolved after 24 hours was evaluated as "20 g ⁇ ", and 100 g of demineralized water was used. A sample in which 0.05 g was dissolved but not 1.00 g was evaluated as 0.05 to 1.00 g.
  • fusing point " ⁇ 45" means that melting
  • the skin contact surface of the top sheet of the above-mentioned sanitary napkin was coated with the above-mentioned blood modifier. Heat each blood modifier to its melting point + 20 ° C if the blood modifier is liquid at room temperature, and if the blood modifier is solid at room temperature, then control seam HMA gun Each blood modifying agent was atomized and applied to the entire skin contact surface of the top sheet so that the basis weight was approximately 5 g / m 2 .
  • FIG. 15 is an electron micrograph of the skin contact surface of the top sheet in the sanitary napkin (No. 2-5) in which the top sheet contains avian C2L oil fatty acid glyceride. As is apparent from FIG. 15, the tri-C2L oil fatty acid glyceride is in the form of fine particles and adheres to the surface of the fiber. The rewet rate and the absorber transfer rate were measured according to the following procedure.
  • Rewet rate (%) 100 ⁇ (weight of filter paper after test ⁇ weight of original filter paper) / 6
  • absorber transfer speed which is the time for blood to transfer from the top sheet to the absorber after the second drop of blood.
  • absorber transfer rate means the time from when blood is introduced into the top sheet to when the red color of blood is not seen on the surface and inside of the top sheet.
  • the rewet rate was 22.7% and the absorber transfer rate was over 60 seconds, but both the glycerin and fatty acid triesters had rewet rates From the fact that it is 7.0% or less and the absorber transfer rate is 8 seconds or less, it can be seen that the absorption performance is greatly improved. However, among triesters of glycerin and fatty acid, NA50 of which the melting point exceeds 45 ° C. shows no significant improvement in the absorption performance.
  • a blood modifying agent having an IOB of about 0.00 to about 0.60, a melting point of about 45 ° C. or less, and an aqueous solubility of about 0.00 to about 0.05 g per 100 g of water at 25 ° C. It was found that the absorption performance was greatly improved.
  • sanitary napkins were worn by a plurality of volunteer subjects.
  • sanitary napkins containing blood modifiers 2-1 to 2-3 there was no tackiness on the top sheet even after menstrual blood absorption, and it was answered that the top sheet was smooth. .
  • Defibrillation blood after blood collection, stirred for about 5 minutes in an Erlenmeyer flask together with glass beads
  • EDTA blood Addition of 0.5 mL of 12% EDTA ⁇ 2K saline to 65 mL of venous blood
  • Serum or plasma Supernatant after centrifuging defibrillated blood or EDTA blood, respectively, at about 1900 G at room temperature for 10 minutes
  • Blood cells Remove the serum from the blood and remove the residual phosphate buffered saline (PBS) ) Washed twice and then added with phosphate buffered saline for the removed serum
  • An absorbent article was produced in the same manner as in Example 2 except that avian C2L oil fatty acid glyceride was applied so as to give a basis weight of approximately 5 g / m 2, and the rewet rate was evaluated for the above various blood. . Three measurements were taken for each blood and the mean value was taken. The results are shown in Table 3 below.
  • Example 2 The same tendency as equine EDTA blood obtained in Example 2 was also obtained in human and sheep blood. The same tendency was also observed in defibrinated blood and EDTA blood.
  • the top sheet containing the blood modifying agent has low blood retention and can be rapidly transferred to the absorber after absorbing blood.
  • Example 4 [Viscosity of blood containing blood modifying agent] The viscosity of the blood containing the blood modifying agent was measured using Rheometric Expansion System ARES (Rheometric Scientific, Inc). 2% by weight of Panaceto 810s was added to equine defibrinated blood, the mixture was lightly stirred to form a sample, the sample was loaded on a parallel plate of 50 mm in diameter, the gap was made 100 ⁇ m, and the viscosity was measured at 37 ⁇ 0.5 ° C. . Because of the parallel plate, the sample was not subjected to a uniform shear rate, but the average shear rate displayed on the instrument was 10 s ⁇ 1 .
  • the viscosity of horse-defibrillated blood containing 2% by mass of Panaceto 810s was 5.9 mPa ⁇ s, while the viscosity of horse-defibrillated blood containing no blood modifying agent was 50.4 mPa ⁇ s.
  • equine defibrinated blood containing 2% by weight of Panaceto 810s reduces the viscosity by about 90% as compared to the case without blood modifying agent.
  • blood contains components such as blood cells and is known to have thixotropy properties, it is considered that the blood modifying agent of the present disclosure can lower the viscosity of blood in a low viscosity region. By reducing the viscosity of blood, it is thought that absorbed menstrual blood can be rapidly transferred from the top sheet to the absorber.
  • Example 5 [Micrograph of blood containing blood modifier] A healthy volunteer's menstrual blood is collected on a food protection wrap film, and in part, Panaceto 810s dispersed in 10 times mass phosphate buffered saline, the concentration of Panaceto 810s is 1% by mass As it was added. The menstrual blood was applied to a slide glass, covered with a cover glass, and the condition of red blood cells was observed with a light microscope. A photomicrograph of menstrual blood containing no blood modifying agent is shown in FIG. 16 (a), and a photomicrograph of menstrual blood containing PANACET 810s is shown in FIG. 16 (b).
  • red blood cells form a lump of rhomsen, etc., but in menstrual blood containing PANACET 810s, the red blood cells are dispersed stably. I understand. Therefore, it is suggested that the blood modifying agent works to stabilize red blood cells in the blood.
  • Example 6 [Surface tension of blood containing blood modifier] The surface tension of blood containing a blood modifying agent was measured by a pendant drop method using a contact angle meter Drop Master 500 manufactured by Kyowa Interface Science Co., Ltd. The surface tension was measured after adding a predetermined amount of blood modifying agent to sheep defibrinated blood and shaking sufficiently. The measurement is automatically performed by the device, but the surface tension ⁇ is obtained by the following equation (see FIG. 17).
  • the density ⁇ is the density test method and density / mass / volume conversion table in JIS K 2249-1995, 5. It was measured at the temperature shown in Table 5 below according to the vibrational density test method. For measurement, DA-505 of Kyoto Electronics Industries Ltd. was used. The results are shown in Table 5.
  • the blood modifying agent has a water solubility of about 0.00 to about 0.05 g per 100 g of water at 25 ° C., but its solubility in water is very low. It can be seen that the surface tension of the blood can be reduced. By lowering the surface tension of the blood, it is considered that the absorbed blood can be rapidly transferred to the absorber without being held between the fibers of the top sheet.

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Materials Engineering (AREA)
  • Physics & Mathematics (AREA)
  • Fluid Mechanics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Absorbent Articles And Supports Therefor (AREA)
PCT/JP2012/082087 2012-02-29 2012-12-11 吸収性物品 Ceased WO2013128755A1 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN201280072752.8A CN104271090B (zh) 2012-02-29 2012-12-11 吸收性物品
US14/381,928 US9375365B2 (en) 2012-02-29 2012-12-11 Absorbent article
EP12869942.8A EP2821038A4 (en) 2012-02-29 2012-12-11 ABSORBENT ARTICLE

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012-044439 2012-02-29
JP2012044439 2012-02-29

Publications (1)

Publication Number Publication Date
WO2013128755A1 true WO2013128755A1 (ja) 2013-09-06

Family

ID=49081974

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2012/082087 Ceased WO2013128755A1 (ja) 2012-02-29 2012-12-11 吸収性物品

Country Status (7)

Country Link
US (1) US9375365B2 (enExample)
EP (1) EP2821038A4 (enExample)
JP (1) JP5843740B2 (enExample)
CN (1) CN104271090B (enExample)
AR (1) AR090176A1 (enExample)
TW (1) TWI572343B (enExample)
WO (1) WO2013128755A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3145051B2 (ja) 1997-03-11 2001-03-12 株式会社荒井製作所 定着ローラ
CN113893094B (zh) 2014-03-06 2023-07-21 宝洁公司 三维基底
JP6395474B2 (ja) * 2014-06-30 2018-09-26 ユニ・チャーム株式会社 吸収性物品
JP6418818B2 (ja) * 2014-06-30 2018-11-07 ユニ・チャーム株式会社 吸収性物品用の表面シート
WO2017034796A1 (en) 2015-08-26 2017-03-02 The Procter & Gamble Company Absorbent articles having three-dimensional substrates and indicia
CN109310532A (zh) 2016-07-01 2019-02-05 宝洁公司 具有改善的顶片干燥度的吸收制品
WO2018048845A1 (en) * 2016-09-09 2018-03-15 The Procter & Gamble Company Three-dimensional apertured substrates
RU2669092C1 (ru) * 2016-12-30 2018-10-08 Ханчжоу Юньонг Санитари Продактс Ко., Лтд. Ультратонкий супервпитывающий детский подгузник

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6456051A (en) 1987-08-26 1989-03-02 Personal Products Co Sanitary napkin
JPH08510665A (ja) * 1993-05-21 1996-11-12 ザ、プロクター、エンド、ギャンブル、カンパニー 染み透り阻止用圧着接合部を有する吸収物品
JPH08322879A (ja) * 1995-06-02 1996-12-10 Procter & Gamble Co:The 生理用ナプキン
JP3091283B2 (ja) 1991-12-09 2000-09-25 花王株式会社 生理用ナプキン
JP2001129019A (ja) * 1999-11-02 2001-05-15 Kao Corp 吸収性物品
JP2006510456A (ja) * 2002-12-18 2006-03-30 ザ プロクター アンド ギャンブル カンパニー 身体清潔効果のための生理用ナプキン
WO2008149771A1 (ja) * 2007-05-30 2008-12-11 Uni-Charm Corporation 吸収性物品
JP5122007B1 (ja) * 2011-03-31 2013-01-16 ユニ・チャーム株式会社 吸収性物品

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3929135A (en) 1974-12-20 1975-12-30 Procter & Gamble Absorptive structure having tapered capillaries
JPS5717081A (en) 1981-05-25 1982-01-28 Noriko Ikegami Electronic interpreter
US4588630A (en) 1984-06-13 1986-05-13 Chicopee Apertured fusible fabrics
US5181563A (en) * 1987-03-16 1993-01-26 Mcneil-Ppc, Inc. Anatomically shaped absorbent pad
EP0304617B1 (en) 1987-07-30 1995-01-11 Kao Corporation Sanitary article
JPH0775616B2 (ja) 1987-07-30 1995-08-16 花王株式会社 衛生用品の表面材
JPH082364B2 (ja) 1987-12-16 1996-01-17 花王株式会社 衛生用品の表面材
JPH0720856B2 (ja) 1988-12-01 1995-03-08 株式会社大塚製薬工場 皮膚の殺菌・清拭用組成物
JP2728921B2 (ja) 1989-03-01 1998-03-18 花王株式会社 凹凸を有する不織布の製造方法
US5334176A (en) 1991-07-23 1994-08-02 The Procter & Gamble Company Absorbent core for use in catamenial products
BR9205330A (pt) 1991-07-23 1993-11-16 Procter & Gamble Artigo absorvente e absorvente feminino de forma encurvada
MA22660A1 (fr) 1991-10-01 1993-04-01 Procter & Gamble Article absorbant comportant des rabats et des zones d'extensibilite differentielle .
JPH065614A (ja) 1992-06-17 1994-01-14 Murata Mfg Co Ltd 熱処理装置
JPH0784697A (ja) 1993-09-10 1995-03-31 Canon Inc 情報処理装置
US5614283A (en) 1994-12-22 1997-03-25 Tredegar Industries Absorbent composite with three-dimensional film surface for use in absorbent disposable products
US5650214A (en) 1996-05-31 1997-07-22 The Procter & Gamble Company Web materials exhibiting elastic-like behavior and soft, cloth-like texture
US5891126A (en) 1996-08-30 1999-04-06 The Procter & Gamble Company Absorbent interlabial device treated with a polysiloxane emollient
JPH1095810A (ja) 1996-09-24 1998-04-14 Oji Paper Co Ltd 高吸水性樹脂及びその製造方法
ZA985679B (en) 1997-06-30 1999-01-26 Procter & Gamble Absorbent article with multi-layered extensible wings
US6277104B1 (en) * 1997-08-25 2001-08-21 Mcneil-Ppc, Inc. Air permeable, liquid impermeable barrier structures and products made therefrom
KR20010024679A (ko) 1997-12-05 2001-03-26 데이비드 엠 모이어 플랩 및 연장성 대역을 갖는 복합 생리대
US6262331B1 (en) 1998-06-05 2001-07-17 The Procter & Gamble Company Absorbent article having a topsheet that includes selectively openable and closable openings
EP1034804A1 (en) 1999-03-05 2000-09-13 The Procter & Gamble Company Articles comprising an oxidising agent and a hemolytic agent
US6730819B1 (en) 1999-03-05 2004-05-04 The Procter & Gamble Company Articles comprising oxidizing and hemolytic agents
US6153209A (en) 1999-09-28 2000-11-28 The Procter & Gamble Company Article having a transferable breathable skin care composition thereon
JP3748743B2 (ja) 1999-10-04 2006-02-22 ユニ・チャーム株式会社 吸収性物品およびその製造方法
JP3576052B2 (ja) * 1999-10-29 2004-10-13 ユニ・チャーム株式会社 使い捨て着用物品に使用する可撓性複合シート
US20010044614A1 (en) 1999-12-23 2001-11-22 Damay Emmanuelle Cecile Reducing agents for feminine care products
JP3701208B2 (ja) 2000-03-13 2005-09-28 ユニ・チャーム株式会社 開孔シートとこの開孔シートを使用した吸収性物品および前記開孔シートの製造方法。
DE60140994D1 (de) 2001-04-17 2010-02-25 Procter & Gamble Saugfähiger Einwegartikel mit einem Wirkstoff zur Übertragung einer Sensation
JP3926587B2 (ja) 2001-07-12 2007-06-06 ユニ・チャーム株式会社 吸収性物品
JP4855606B2 (ja) 2001-08-10 2012-01-18 ユニ・チャーム株式会社 吸収性物品
SE519783C2 (sv) 2001-08-31 2003-04-08 Sca Hygiene Prod Ab Absorberande alster innefattande öppningar i absorptionskroppen
US20030082219A1 (en) 2001-10-01 2003-05-01 The Procter & Gamble Company Skin care compositions comprising low concentrations of skin treatment agents
SG103382A1 (en) 2002-01-11 2004-04-29 Uni Charm Corp Colored absorbent article
JP4693847B2 (ja) 2002-03-26 2011-06-01 ユニ・チャーム株式会社 吸収性物品およびその製造方法
JP4278963B2 (ja) 2002-03-26 2009-06-17 ユニ・チャーム株式会社 吸収性物品
DE60231704D1 (de) * 2002-06-12 2009-05-07 Sca Hygiene Prod Ab Absorbierender Artikel mit einer Hautpflegezusammensetzung
JP3949020B2 (ja) 2002-07-19 2007-07-25 花王株式会社 吸収性物品
US9035123B2 (en) 2002-10-01 2015-05-19 The Procter & Gamble Company Absorbent article having a lotioned topsheet
JP2005095759A (ja) 2003-09-24 2005-04-14 San-Dia Polymer Ltd 吸収剤とこれを用いてなる吸収性物品
US20050096614A1 (en) 2003-10-29 2005-05-05 Perez Roberto C. Cover layer for an absorbent article
JP4476102B2 (ja) 2003-12-11 2010-06-09 花王株式会社 吸収性物品の表面シート
EP1778146B1 (en) 2004-06-21 2016-12-28 The Procter and Gamble Company Absorbent article with lotion-containing topsheet
JP4459013B2 (ja) 2004-10-20 2010-04-28 花王株式会社 吸収性物品
US8211078B2 (en) 2005-02-17 2012-07-03 The Procter And Gamble Company Sanitary napkins capable of taking complex three-dimensional shape in use
JP4514630B2 (ja) 2005-03-16 2010-07-28 花王株式会社 吸収性物品の表面シート
JP4523866B2 (ja) 2005-03-31 2010-08-11 ユニ・チャーム株式会社 吸収性物品
US8481806B2 (en) 2005-06-02 2013-07-09 The Procter And Gamble Company Absorbent article having traverse reinforcing element
JP4792249B2 (ja) 2005-07-11 2011-10-12 ユニ・チャーム株式会社 体液吸収性物品
CN101400329B (zh) 2006-03-14 2014-02-19 宝洁公司 具有洗剂的吸收制品
JP5069890B2 (ja) 2006-06-23 2012-11-07 ユニ・チャーム株式会社 不織布
JP5123513B2 (ja) 2006-06-23 2013-01-23 ユニ・チャーム株式会社 吸収体
JP5328089B2 (ja) 2006-06-23 2013-10-30 ユニ・チャーム株式会社 多層不織布及び多層不織布の製造方法
JP5069891B2 (ja) 2006-06-23 2012-11-07 ユニ・チャーム株式会社 不織布
KR101395379B1 (ko) 2006-06-23 2014-05-14 유니챰 가부시키가이샤 흡수성 물품
JP5123497B2 (ja) 2006-06-23 2013-01-23 ユニ・チャーム株式会社 不織布、不織布製造方法及び不織布製造装置
JP5328088B2 (ja) 2006-06-23 2013-10-30 ユニ・チャーム株式会社 不織布
JP5123511B2 (ja) 2006-06-23 2013-01-23 ユニ・チャーム株式会社 不織布
JP5123505B2 (ja) 2006-06-23 2013-01-23 ユニ・チャーム株式会社 不織布
JP5154048B2 (ja) 2006-06-23 2013-02-27 ユニ・チャーム株式会社 不織布
JP5123512B2 (ja) 2006-06-23 2013-01-23 ユニ・チャーム株式会社 不織布
EP2036521A4 (en) 2006-07-05 2012-06-20 Kao Corp ABSORBENT ARTICLE
JP5021380B2 (ja) 2006-07-05 2012-09-05 花王株式会社 吸収性物品
JP4986673B2 (ja) 2007-03-27 2012-07-25 花王株式会社 吸収性物品
JP4939196B2 (ja) 2006-12-12 2012-05-23 ユニ・チャーム株式会社 不織布、不織布の製造方法及び吸収性物品
ATE528425T1 (de) 2006-12-05 2011-10-15 Uni Charm Corp Vliesstoff, verfahren zur herstellung von vliesstoff sowie saugkörper
JP4939192B2 (ja) 2006-12-05 2012-05-23 ユニ・チャーム株式会社 不織布、不織布の製造方法及び吸収性物品
EP2092918A4 (en) 2006-12-13 2012-06-27 Uni Charm Corp ABSORBENT ARTICLE
AR065378A1 (es) 2007-02-16 2009-06-03 Procter & Gamble Articulo absorbente con locion que comprende un material de polipropilenglicol
JP4979423B2 (ja) 2007-03-20 2012-07-18 花王株式会社 吸収性物品
JP4979424B2 (ja) 2007-03-20 2012-07-18 花王株式会社 吸収性物品
WO2008133067A1 (ja) 2007-04-17 2008-11-06 Uni-Charm Corporation 不織布、不織布製造方法、及び、吸収性物品
JP5114087B2 (ja) 2007-04-17 2013-01-09 ユニ・チャーム株式会社 不織布、及び、吸収性物品
JP4879074B2 (ja) 2007-04-17 2012-02-15 ユニ・チャーム株式会社 不織布製造方法
US20080281287A1 (en) 2007-05-08 2008-11-13 Marcelo Ana Maria Elena R Sanitary napkin including body-facing protrusions for preventing side leakage and obliquely arranged embossed channels
EP1992366B1 (en) 2007-05-15 2011-07-06 The Procter & Gamble Company Use of a lotion composition on an absorbent article for reducing adherence of feces or menses to the skin
JP5568210B2 (ja) 2007-06-13 2014-08-06 ユニ・チャーム株式会社 不織布シートの製造方法
JP5497987B2 (ja) 2007-06-22 2014-05-21 ユニ・チャーム株式会社 不織布およびその製造方法
JP2009005767A (ja) 2007-06-26 2009-01-15 Kao Corp 吸収性物品
US7942858B2 (en) 2007-07-03 2011-05-17 Mcneil-Ppc, Inc. Sanitary napkin including body-facing protrusions and arcuately arranged embossed channels
JP4652387B2 (ja) 2007-10-03 2011-03-16 王子製紙株式会社 折り返し部を有する吸収体製品
CN101945674B (zh) * 2008-02-15 2013-11-27 宝洁公司 具有包含聚丙二醇材料的洗剂的吸收制品
JP2009201878A (ja) 2008-02-29 2009-09-10 Uni Charm Corp 吸収性物品
JP5173616B2 (ja) 2008-06-10 2013-04-03 花王株式会社 吸収性物品
JP5371361B2 (ja) 2008-10-10 2013-12-18 ユニ・チャーム株式会社 吸収性物品及び吸収性物品の製造方法
JP5455363B2 (ja) 2008-12-25 2014-03-26 ユニ・チャーム株式会社 薄型吸収性物品
JP5520124B2 (ja) 2009-05-14 2014-06-11 ユニ・チャーム株式会社 透液性繊維不織布
JP5401177B2 (ja) 2009-06-04 2014-01-29 花王株式会社 吸収性物品
CN102427790B (zh) 2009-05-20 2016-01-06 花王株式会社 吸收体和吸收性物品
JP5590834B2 (ja) 2009-08-11 2014-09-17 ユニ・チャーム株式会社 不織布およびその製造方法
JP2011067484A (ja) 2009-09-28 2011-04-07 Kao Corp 吸収性物品
JP5623052B2 (ja) 2009-09-29 2014-11-12 ユニ・チャーム株式会社 不織布の製造方法
JP5530693B2 (ja) 2009-09-30 2014-06-25 大王製紙株式会社 吸収性物品
JP5421720B2 (ja) 2009-10-09 2014-02-19 ユニ・チャーム株式会社 不織布
JP5395630B2 (ja) 2009-11-13 2014-01-22 花王株式会社 吸収性物品
JP5466489B2 (ja) 2009-11-16 2014-04-09 花王株式会社 吸収性物品
JP5551926B2 (ja) 2009-12-09 2014-07-16 花王株式会社 吸収性物品
JP5506520B2 (ja) 2010-04-16 2014-05-28 ユニ・チャーム株式会社 伸長性繊維と伸縮性繊維とを含む、凹凸を有する不織布、及び当該不織布を製造する方法
JP5506519B2 (ja) 2010-04-16 2014-05-28 ユニ・チャーム株式会社 凹凸を有する不織布を簡易に製造する方法、及び不織布を簡易に加工する方法
JP5749907B2 (ja) 2010-08-31 2015-07-15 ユニ・チャーム株式会社 吸収性物品及び生理用ナプキン
US8921640B2 (en) * 2010-10-08 2014-12-30 The Procter & Gamble Company Absorbent article with philic anhydrous lotion
JP5916327B2 (ja) * 2011-09-30 2016-05-11 ユニ・チャーム株式会社 吸収性物品
JP5745377B2 (ja) * 2011-09-30 2015-07-08 ユニ・チャーム株式会社 吸収性物品
JP5709789B2 (ja) * 2012-03-30 2015-04-30 ユニ・チャーム株式会社 吸収性物品
JP5847055B2 (ja) * 2012-02-29 2016-01-20 ユニ・チャーム株式会社 吸収性物品
JP5762345B2 (ja) * 2012-03-30 2015-08-12 ユニ・チャーム株式会社 吸収性物品
JP5713950B2 (ja) * 2012-03-30 2015-05-07 ユニ・チャーム株式会社 吸収性物品
JP5726123B2 (ja) * 2012-03-30 2015-05-27 ユニ・チャーム株式会社 吸収性物品

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6456051A (en) 1987-08-26 1989-03-02 Personal Products Co Sanitary napkin
JP3091283B2 (ja) 1991-12-09 2000-09-25 花王株式会社 生理用ナプキン
JPH08510665A (ja) * 1993-05-21 1996-11-12 ザ、プロクター、エンド、ギャンブル、カンパニー 染み透り阻止用圧着接合部を有する吸収物品
JPH08322879A (ja) * 1995-06-02 1996-12-10 Procter & Gamble Co:The 生理用ナプキン
JP2001129019A (ja) * 1999-11-02 2001-05-15 Kao Corp 吸収性物品
JP2006510456A (ja) * 2002-12-18 2006-03-30 ザ プロクター アンド ギャンブル カンパニー 身体清潔効果のための生理用ナプキン
WO2008149771A1 (ja) * 2007-05-30 2008-12-11 Uni-Charm Corporation 吸収性物品
JP5122007B1 (ja) * 2011-03-31 2013-01-16 ユニ・チャーム株式会社 吸収性物品

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FUJITA A.: "Organic compound predictions and organic paradigms", KAGAKU NO RYOIKI, vol. 11, no. 10, 1957, pages 719 - 725
See also references of EP2821038A4 *

Also Published As

Publication number Publication date
CN104271090B (zh) 2016-03-02
US9375365B2 (en) 2016-06-28
US20150065984A1 (en) 2015-03-05
EP2821038A1 (en) 2015-01-07
TW201406359A (zh) 2014-02-16
TWI572343B (zh) 2017-03-01
CN104271090A (zh) 2015-01-07
AR090176A1 (es) 2014-10-22
JP2013208419A (ja) 2013-10-10
EP2821038A4 (en) 2015-09-30
JP5843740B2 (ja) 2016-01-13

Similar Documents

Publication Publication Date Title
JP5713951B2 (ja) 吸収性物品
JP5925015B2 (ja) 吸収性物品
JP5847055B2 (ja) 吸収性物品
JP5843740B2 (ja) 吸収性物品
WO2013129327A1 (ja) 吸収性物品
JP5963639B2 (ja) 吸収性物品
JP6037606B2 (ja) 吸収性物品、吸収性物品のトップシートおよびそのトップシートの製造方法
JP5916327B2 (ja) 吸収性物品
JP5709788B2 (ja) 吸収性物品
JP6041473B2 (ja) 吸収性物品
JP2013078376A (ja) 吸収性物品
JP5769655B2 (ja) 吸収性物品
JP6041472B2 (ja) 吸収性物品、吸収性物品のトップシートおよびそのトップシートの製造方法
JP5762346B2 (ja) 吸収性物品
WO2013129332A1 (ja) 吸収性物品
JP2013208410A (ja) 吸収性物品
WO2013129326A1 (ja) 吸収性物品
JP2013212153A (ja) 吸収性物品

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12869942

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2012869942

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 14381928

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE